Defining and Reporting Hypoglycemia in Diabetes: A re Association Workgroup on Hypoglycemia

Diabetes Care

28, 1245-1249

DOI: 10.2337/diacare.28.5.1245

Citation Report

#	Article	IF	Citations
1	Hypoglycemia: A Complication of Diabetes Therapy in Children. Seminars in Pediatric Neurology, 2005, 12, 163-177.	1.0	1
2	Insulin secretagogues: Who, what, when, and how?. Current Diabetes Reports, 2005, 5, 329-332.	1.7	4
3	Translation of successful diabetes-related lifestyle interventions from research to practice. Current Diabetes Reports, 2005, 5, 363-365.	1.7	1
4	Comparison of a Needle-Type and a Microdialysis Continuous Glucose Monitor in Type 1 Diabetic Patients. Diabetes Care, 2005, 28, 2871-2876.	4.3	105
5	Hypoglycemia: A Complication of Diabetes Therapy in Children. Pediatric Clinics of North America, 2005, 52, 1705-1733.	0.9	33
6	Perioperative Blood Glucose Control. Perioperative Nursing Clinics, 2006, 1, 223-234.	0.1	2
7	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17444-17449.	3.3	166
8	Evaluation of a New Measure of Blood Glucose Variability in Diabetes. Diabetes Care, 2006, 29, 2433-2438.	4.3	293
9	Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Drugs, 2006, 66, 31-49.	4.9	85
10	Rush University Guidelines and Protocols for the Management of Hyperglycemia in Hospitalized Patients. The Diabetes Educator, 2006, 32, 954-962.	2.6	33
11	Evolution of a Diabetes Inpatient Safety Committee. Endocrine Practice, 2006, 12, 91-99.	1.1	55
13	Unrecognised hypoglycaemia in children and adolescents with type 1 diabetes using the continuous glucose monitoring system: Prevalence and contributors. Journal of Paediatrics and Child Health, 2006, 42, 758-763.	0.4	29
14	Is glycemic variability important to assessing antidiabetes therapies?. Current Diabetes Reports, 2006, 6, 350-356.	1.7	11
15	A Practical Approach to Hyperglycemia Management in the Intensive Care Unit: Evaluation of an Intensive Insulin Infusion Protocol. Pharmacotherapy, 2006, 26, 1410-1420.	1.2	27
17	Nocturnal Hypoglycemia in Type 1 Diabetes: An Assessment of Preventive Bedtime Treatments. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2087-2092.	1.8	82
19	Diabetes Disease Management in Medicaid Managed Care: A Program Evaluation. Disease Management: DM, 2006, 9, 144-156.	1.0	15
20	Glucose Variability and Complications. Diabetes Care, 2006, 29, 1707-1709.	4.3	31
21	Hypoglycemia in childhood type 1 diabetes mellitus: Understanding and managing the dark side of intensive insulin therapy. Insulin, 2007, 2, 157-165.	0.2	1

#	Article	IF	Citations
22	Management of Diabetes-related Hypoglycemia. Southern Medical Journal, 2007, 100, 183-194.	0.3	24
23	Code: Community Diabetes Education for Uninsured Mexican Americans. Baylor University Medical Center Proceedings, 2007, 20, 111-117.	0.2	28
24	Physiological and Behavioral Aspects of Glycemic Control and Hypoglycemia in Diabetes. Southern Medical Journal, 2007, 100, 175-182.	0.3	17
25	Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. Journal of Hospital Medicine, 2007, 2, 234-240.	0.7	78
26	Nocturnal hypoglycaemia in TypeÂ1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associations. Diabetic Medicine, 2007, 24, 527-532.	1.2	49
27	A randomized pilot study in TypeÂ1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabetic Medicine, 2007, 24, 778-783.	1.2	32
28	Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovascular Disorders, 2007, 7, 31.	0.7	11
29	Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 2007, 50, 1148-1155.	2.9	355
30	Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia, 2007, 50, 2553-2561.	2.9	193
31	Randomized controlled clinical trials of psychological interventions to improve glycemic control in pediatric and adult patients with T1DM. Current Diabetes Reports, 2007, 7, 101-103.	1.7	0
32	Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. International Journal of Clinical Pharmacy, 2008, 30, 876-883.	1.4	87
33	Fear of Hypoglycemia in Parents of Young Children with Type 1 Diabetes Mellitus. Journal of Clinical Psychology in Medical Settings, 2008, 15, 252-259.	0.8	95
34	Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocrine Disorders, 2008, 8, 4.	0.9	214
35	Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2008, 24, 257-285.	1.7	12
36	An adaptive clinical Type 1 diabetes control protocol to optimize conventional selfâ€monitoring blood glucose and multiple dailyâ€injection therapy. International Journal of Adaptive Control and Signal Processing, 2009, 23, 408-434.	2.3	0
37	Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: Impact on thyroid function, metabolic control and pregnancy outcome. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1336-1342.	1.3	14
38	CARE OF PATIENTS WITH DIABETES MELLITUS IN LONGâ€TERM CARE FACILITIES IN TAIWAN: DIAGNOSIS, GLYCEMIC CONTROL, HYPOGLYCEMIA, AND FUNCTIONAL STATUS. Journal of the American Geriatrics Society, 2008, 56, 1975-1976.	1.3	25
39	DIABETES MELLITUS AND DEMENTIA: ADVOCATING AN ANNUAL COGNITIVE SCREENING IN PATIENTS WITH DIABETES MELLITUS. Journal of the American Geriatrics Society, 2008, 56, 1976-1977.	1.3	11

#	Article	IF	CITATIONS
40	Hypoglycaemia in Type 2 diabetes. Diabetic Medicine, 2008, 25, 245-254.	1.2	427
41	Severe hypoglycaemia and glycaemic control in TypeÂ1 diabetes: metaâ€analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine, 2008, 25, 765-774.	1.2	550
42	Lower levels of circulating IGFâ€i in TypeÂ1 diabetic women with frequent severe hypoglycaemia during pregnancy. Diabetic Medicine, 2008, 25, 826-833.	1.2	20
43	Nutritional management of children and adolescents on insulin pump therapy – a survey of Australian Practice. Pediatric Diabetes, 2008, 9, 96-103.	1.2	4
44	Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 2008, 9, 165-174.	1.2	95
45	Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes, 2008, 6, 73.	1.0	60
46	Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology, 2008, 46, S47-S53.	1.8	115
47	Managing Preexisting Diabetes for Pregnancy. Diabetes Care, 2008, 31, 1060-1079.	4.3	425
48	Weight management in basal-bolus insulin therapy for type 2 diabetes mellitus: The deep south diabetes program. Insulin, 2008, 3, 95-108.	0.2	2
49	Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surgery for Obesity and Related Diseases, 2008, 4, 492-499.	1.0	199
50	Les conséquences de l'hypoglycémie. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2008, 17, 437-441.	0.1	3
51	Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2008, 31, 2271-2272.	4.3	17
52	Statistical Hypoglycemia Prediction. Journal of Diabetes Science and Technology, 2008, 2, 612-621.	1.3	44
53	The Barrier of Hypoglycemia in Diabetes. Diabetes, 2008, 57, 3169-3176.	0.3	612
54	<i>In Silico</i> Simulation of Long-Term Type 1 Diabetes Glycemic Control Treatment Outcomes. Journal of Diabetes Science and Technology, 2008, 2, 436-449.	1.3	8
55	Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes. Diabetes Care, 2008, 31, S113-S120.	4.3	42
56	The DURABLE Trial Study Design: Comparing the Safety, Efficacy, and Durability of Insulin Glargine to Insulin Lispro Mix 75/25 Added to Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology, 2008, 2, 831-838.	1.3	21
57	Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes. Diabetes Care, 2008, 31, S140-S145.	4.3	93

#	Article	IF	CITATIONS
58	Hospitalization and Discharge Education of Emergency Department Patients With Hypoglycemia. The Diabetes Educator, 2008, 34, 683-691.	2.6	26
59	Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis. Annals of Pharmacotherapy, 2008, 42, 1541-1551.	0.9	23
60	How to Assess and Compare the Accuracy of Continuous Glucose Monitors?. Diabetes Technology and Therapeutics, 2008, 10, 57-68.	2.4	45
61	Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weightâ€based dose of insulin Aspart. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 739-744.	0.6	3
62	Pramlintide Reduces the Risks Associated with Glucose Variability in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2008, 10, 391-396.	2.4	9
63	Hypoglycemia in Pregnant Women With Type 1 Diabetes. Diabetes Care, 2008, 31, 9-14.	4.3	168
66	Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vascular Health and Risk Management, 2008, , 121.	1.0	4
67	Revisiting hypoglycaemia. Practice Nursing, 2009, 20, 516-518.	0.1	5
68	DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results. Diabetes Care, 2009, 32, 1007-1013.	4.3	119
69	Statistical Tools to Analyze Continuous Glucose Monitor Data. Diabetes Technology and Therapeutics, 2009, 11, S-45-S-54.	2.4	190
70	Reference Values for Continuous Glucose Monitoring in Chinese Subjects. Diabetes Care, 2009, 32, 1188-1193.	4.3	110
71	Accuracy and Reliability of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes During Recreational Diving. Diabetes Technology and Therapeutics, 2009, 11, 493-497.	2.4	22
72	Hypoglycemia: From the Laboratory to the Clinic. Diabetes Care, 2009, 32, 1364-1371.	4.3	36
73	An Overview of Hypoglycemia in the Critically Ill. Journal of Diabetes Science and Technology, 2009, 3, 1242-1249.	1.3	63
74	Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a clinical audit. Diabetes Care, 2009, 32, 1196-1198.	4.3	97
75	Relationship Between Spontaneous and latrogenic Hypoglycemia and Mortality in Patients Hospitalized With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2009, 301, 1556.	3.8	310
76	Retropharyngeal abscess secondary to a foreign body. Emergency Medicine Journal, 2009, 26, 723-723.	0.4	0
77	Managing Hypoglycemia in the School Setting. NASN School Nurse (Print), 2009, 24, 190-193.	0.4	0

#	Article	IF	CITATIONS
78	Diabetes and Employment. Diabetes Care, 2009, 32, S80-S84.	4.3	7
79	Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Circulation, 2009, 120, 2429-2437.	1.6	121
80	Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 564-569.	1.8	150
81	24-Hour observational ward management of diabetic patients presenting with hypoglycaemia: a prospective observational study. Emergency Medicine Journal, 2009, 26, 719-723.	0.4	2
82	Perceptions of resident physicians about management of inpatient hyperglycemia in an urban hospital. Journal of Hospital Medicine, 2009, 4, E1-E8.	0.7	50
83	Glycaemic profile characteristics and frequency of impaired awareness of hypoglycaemia in subjects with T1D and repeated hypoglycaemic events. Acta Diabetologica, 2009, 46, 291-293.	1.2	13
84	Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia, 2009, 52, 38-41.	2.9	49
85	Preventing hypoglycaemia: what is the appropriate glucose alert value?. Diabetologia, 2009, 52, 35-37.	2.9	72
86	Defining hypoglycaemia: what level has clinical relevance?. Diabetologia, 2009, 52, 31-34.	2.9	66
87	Use of therapeutic responses to glucose replacement to predict glucose patterns in diabetic patients presenting with severe hypoglycaemia. International Journal of Clinical Practice, 2009, 63, 1161-1166.	0.8	1
88	Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 2009, 10, 134-145.	1.2	130
89	The European Exenatide study of longâ€term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes, Obesity and Metabolism, 2009, 11, 1131-1137.	2.2	7
90	Patientâ€reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes, Obesity and Metabolism, 2009, 11, 1138-1144.	2.2	67
91	NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabetic Medicine, 2009, 26, 1-4.	1.2	33
92	Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucoseâ€kowering agents. Diabetic Medicine, 2009, 26, 1147-1155.	1.2	27
94	Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 709-728.	1.8	976
95	Severe hypoglycaemia during pregnancy in women with type 1 diabetes: Possible role of renin–angiotensin system activity?. Diabetes Research and Clinical Practice, 2009, 84, 61-67.	1.1	11
96	Mobile diabetes intervention study: Testing a personalized treatment/behavioral communication intervention for blood glucose control. Contemporary Clinical Trials, 2009, 30, 334-346.	0.8	65

#	ARTICLE	IF	Citations
97	Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. American Journal of Emergency Medicine, 2009, 27, 968-974.	0.7	35
99	Glucose metabolism in children: influence of age, fasting, and infectious diseases. Metabolism: Clinical and Experimental, 2009, 58, 1356-1365.	1.5	25
100	Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health and Quality of Life Outcomes, 2009, 7, 91.	1.0	55
101	Chapter 3 Analytical Methods for the Retrieval and Interpretation of Continuous Glucose Monitoring Data in Diabetes. Methods in Enzymology, 2009, 454, 69-86.	0.4	9
102	Presence of <i>CYP2C9*3</i> allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics, 2009, 10, 1781-1787.	0.6	84
103	Type 1 Diabetes., 2009,, 3-32.		0
104	Comparative Effectiveness Research in DARTNet Primary Care Practices. Medical Care, 2010, 48, S39-S44.	1.1	22
105	Preventing Post-Exercise Nocturnal Hypoglycemia in Children with Type 1 Diabetes. Journal of Pediatrics, 2010, 157, 784-788.e1.	0.9	98
106	Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial. Clinical Therapeutics, 2010, 32, 896-908.	1.1	42
107	Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. International Journal of Clinical Practice, 2010, 64, 1121-1129.	0.8	65
108	Pregnancyâ€induced sightâ€threatening diabetic retinopathy in women with Type 1 diabetes. Diabetic Medicine, 2010, 27, 431-435.	1.2	101
109	Comparison of insulin lispro protamine suspension and insulin detemir in basalâ \in bolus therapy in patients with Typeâ \in f1 diabetes. Diabetic Medicine, 2010, 27, 563-569.	1.2	17
110	Frequency of symptomatic and asymptomatic hypoglycaemia in Type $\hat{a} \in f1$ diabetes: effect of impaired awareness of hypoglycaemia. Diabetic Medicine, 2011, 28, 352-355.	1.2	34
112	Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes. Aging Health, 2010, 6, 31-40.	0.3	2
113	Risk Factors for Recurrent Hypoglycemia in Hospitalized Diabetic Patients Admitted for Severe Hypoglycemia. Yonsei Medical Journal, 2010, 51, 367.	0.9	36
114	Diabetes and Hyperglycemia Quality Improvement Efforts in Hospitals in the United States: Current Status, Practice Variation, and Barriers to Implementation. Endocrine Practice, 2010, 16, 219-230.	1.1	49
115	Diabetes and Employment. Diabetes Care, 2010, 33, S82-S86.	4.3	2
116	Silent Myocardial Infarction and Hypoglycaemia. , 2010, 20, 2-6.		2

#	Article	IF	CITATIONS
117	Neuroendocrine responses to hypoglycemia. Annals of the New York Academy of Sciences, 2010, 1212, 12-28.	1.8	104
119	Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green "Traffic―Lights Using Continuous Glucose Monitoring and Insulin Pump Data. Journal of Diabetes Science and Technology, 2010, 4, 1146-1155.	1.3	80
120	Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Current Medical Research and Opinion, 2010, 26, 1333-1342.	0.9	28
121	Analysis of Hemodialysis-Associated Hypoglycemia in Patients with Type 2 Diabetes Using a Continuous Glucose Monitoring System. Diabetes Technology and Therapeutics, 2010, 12, 801-807.	2.4	45
122	Tailoring adverse drug event surveillance to the paediatric inpatient. BMJ Quality and Safety, 2010, 19, e40-e40.	1.8	5
123	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ: British Medical Journal, 2010, 340, b5444-b5444.	2.4	359
124	Hypoglycemia in Type 1 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America, 2010, 39, 641-654.	1.2	144
126	Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2240-2247.	1.8	148
127	International recommendations for glucose control in adult non diabetic critically ill patients. Critical Care, 2010, 14, R166.	2.5	101
128	Hospital hypoglycemia: From observation to action. Insulin, 2010, 5, 16-36.	0.2	12
129	Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes and Metabolism, 2010, 36, 409-413.	1.4	22
130	Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes and Metabolism, 2010, 36, 409-413. Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, S64-S74.	1.4	22
	diabetic patients treated with a portable pump. Diabetes and Metabolism, 2010, 36, 409-413.		
130	diabetic patients treated with a portable pump. Diabetes and Metabolism, 2010, 36, 409-413. Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, S64-S74. Glucose meters: evaluation of the new formulation measuring strips from Roche (Accu-Chek) and	1.4	112
130	diabetic patients treated with a portable pump. Diabetes and Metabolism, 2010, 36, 409-413. Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, S64-S74. Glucose meters: evaluation of the new formulation measuring strips from Roche (Accu-Chek) and Abbott (MediSense). Annals of Clinical Biochemistry, 2010, 47, 358-365. Sustained Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Subjects with Recurrent Non-Severe and Severe Hypoglycemia and Hypoglycemia Unawareness: A Pilot Study. Diabetes	0.8	112 24
130 131 132	Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, 409-413. Glucose meters: evaluation of the new formulation measuring strips from Roche (Accu-Chek) and Abbott (MediSense). Annals of Clinical Biochemistry, 2010, 47, 358-365. Sustained Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Subjects with Recurrent Non-Severe and Severe Hypoglycemia and Hypoglycemia Unawareness: A Pilot Study. Diabetes Technology and Therapeutics, 2010, 12, 517-521. Economic impact of hypoglycemia on healthcare in Spain. Expert Review of Pharmacoeconomics and	1.4 0.8 2.4	112 24 32
130 131 132	Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, 409-413. Impaired awareness of hypoglycaemia: a review. Diabetes and Metabolism, 2010, 36, S64-S74. Glucose meters: evaluation of the new formulation measuring strips from Roche (Accu-Chek) and Abbott (MediSense). Annals of Clinical Biochemistry, 2010, 47, 358-365. Sustained Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Subjects with Recurrent Non-Severe and Severe Hypoglycemia and Hypoglycemia Unawareness: A Pilot Study. Diabetes Technology and Therapeutics, 2010, 12, 517-521. Economic impact of hypoglycemia on healthcare in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 649-660. Idiopathic reactive hypoglycaemia – Prevalence and effect of fibre on glucose excursions.	1.4 0.8 2.4 0.7	112 24 32 39

#	Article	IF	CITATIONS
137	The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 813-818.	2.4	147
138	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus., 2011,, CD008143.		57
139	The 4th International Conference onAdvanced Technologies & Treatments for DiabetesLondon, UK/February 16–19, 2011. Diabetes Technology and Therapeutics, 2011, 13, 173-293.	2.4	6
141	The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management. Value in Health, 2011, 14, 665-671.	0.1	240
142	Drug-Induced Hypoglycaemia. Drug Safety, 2011, 34, 21-45.	1.4	70
143	Diabetes Management and Hypoglycemia in Safety Sensitive Jobs. Safety and Health at Work, 2011, 2, 9-16.	0.3	13
144	Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities. American Journal of Medicine, 2011, 124, 1028-1035.	0.6	146
145	Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2011, 91, 363-370.	1.1	74
146	Hypoglycemia in critically ill adults - association yes, causation not proven. Critical Care, 2011, 15, 1012.	2.5	5
148	Hypoglycaemia: a case report. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2011, 3, 696-700.	0.0	0
149	The Experience of Hypoglycaemia and Strategies Used For Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review. JBI Library of Systematic Reviews, 2011, 9, 2063-2104.	0.1	0
150	Hypoglycemia Revisited in the Acute Care Setting. Yonsei Medical Journal, 2011, 52, 898.	0.9	17
151	Increasing Trend in the Number of Severe Hypoglycemia Patients in Korea. Diabetes and Metabolism Journal, 2011, 35, 166.	1.8	33
153	Unit 4. Article 2 Hypoglycaemia unawareness. Practice Nursing, 2011, 22, 5-8.	0.1	0
154	TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT., 0,, 35-61.		0
155	Hypoglycemia in Glyburide-Treated Gestational Diabetes. Obstetrics and Gynecology, 2011, 117, 349-353.	1.2	15
157	Variables associated with severe hypoglycemia in children and adolescents with type 1 diabetes: a population-based study. Pediatric Diabetes, 2011, 12, 4-10.	1.2	20
158	Effective treatment of hypoglycemia in children with type 1 diabetes: a randomized controlled clinical trial. Pediatric Diabetes, $2011,12,381-387.$	1.2	43

#	Article	IF	CITATIONS
159	Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes, Obesity and Metabolism, 2011, 13, 75-80.	2.2	34
160	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes, Obesity and Metabolism, 2011, 13, 1149-1157.	2.2	12
161	Effect of carbohydrate digestibility on appetite and its relationship to postprandial blood glucose and insulin levels. European Journal of Clinical Nutrition, 2011, 65, 47-54.	1.3	24
162	Prevalence of Nocturnal Hypoglycemia in Pediatric Type 1 Diabetes: A Pilot Study Using Continuous Glucose Monitoring. Journal of Pediatrics, 2011, 159, 297-302.e1.	0.9	35
163	Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy, 2011, 45, 850-860.	0.9	54
164	Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. European Journal of Clinical Pharmacology, 2011, 67, 471-476.	0.8	52
165	Intensified insulin therapy during fasting of Ramadan in type 1 diabetic patients. International Journal of Diabetes in Developing Countries, 2011, 31, 216-222.	0.3	2
166	Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Therapy, 2011, 2, 51-66.	1.2	31
168	Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Research Notes, 2011, 4, 251.	0.6	108
169	Treatment of inpatient hyperglycemia beginning in the emergency department: A randomized trial using insulins aspart and detemir compared with usual care. Journal of Hospital Medicine, 2011, 6, 279-284.	0.7	25
170	Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opinion on Pharmacotherapy, 2011, 12, 2161-2175.	0.9	33
171	Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ: British Medical Journal, 2011, 343, d3805-d3805.	2.4	442
172	Recent Advances in the Prevention of Hypoglycemia in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 1177-1186.	2.4	9
173	Effect of Administration Time of Exenatide on Satiety Responses, Blood Glucose, and Adverse Events in Healthy Volunteers. Journal of Clinical Pharmacology, 2011, 51, 165-172.	1.0	15
174	Hypoglycemia and glycemic variability among children with acute lymphoblastic leukemia during maintenance therapy. Leukemia and Lymphoma, 2011, 52, 1704-1710.	0.6	6
175	The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial. Diabetes Care, 2011, 34, 249-255.	4.3	40
176	Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia. Diabetes Spectrum, 2011, 24, 171-177.	0.4	47
177	Recognizing Hypoglycemia in Children Through Automated Adverse-Event Detection. Pediatrics, 2011, 127, e1035-e1041.	1.0	28

#	Article	IF	CITATIONS
178	Outcome Measures for Outpatient Hypoglycemia Prevention Studies. Journal of Diabetes Science and Technology, 2011, 5, 999-1004.	1.3	13
179	Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. Diabetes Care, 2011, 34, 2403-2405.	4.3	102
180	Diabetes and Employment. Diabetes Care, 2011, 34, S82-S86.	4.3	9
181	Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 604-606.	4.3	76
182	Diabetes and Driving. Diabetes Care, 2012, 35, S81-S86.	4.3	44
183	Hypoglycemia in type 2 diabetes: Standpoint of an experts′ committee (India hypoglycemia study group). Indian Journal of Endocrinology and Metabolism, 2012, 16, 894.	0.2	9
184	Diabetes and Employment. Diabetes Care, 2012, 35, S94-S98.	4.3	17
185	Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia. Diabetes Care, 2012, 35, 1897-1901.	4.3	458
186	Risk Factors for Inpatient Hypoglycemia during Subcutaneous Insulin Therapy in Non-Critically Ill Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology, 2012, 6, 1022-1029.	1.3	61
187	Strategies to Limit the Effect of Hypoglycemia on Diabetes Control: Identifying and Reducing the Risks. Clinical Diabetes, 2012, 30, 28-33.	1.2	12
188	Insulin Therapy in Home Health. Home Health Care Management and Practice, 2012, 24, 298-308.	0.4	0
189	Online, Direct-to-Consumer Access to Insulin: Patient Safety Considerations and Reform. Journal of Diabetes Science and Technology, 2012, 6, 1503-1506.	1.3	6
190	The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. Journal of Medical Economics, 2012, 15, 869-877.	1.0	25
191	Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecological Endocrinology, 2012, 28, 529-532.	0.7	26
192	Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 113-124.	1.4	25
193	Evaluation of a new durable insulin pen with memory function among people with diabetes and healthcare professionals. Expert Opinion on Drug Delivery, 2012, 9, 355-366.	2.4	14
194	Clinically Relevant Hypoglycemia Prediction Metrics for Event Mitigation. Diabetes Technology and Therapeutics, 2012, 14, 719-727.	2.4	8
195	Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects. Diabetes Care, 2012, 35, 676-682.	4.3	177

#	Article	IF	CITATIONS
196	No Effect of Insulin Pen with Memory Function on Glycemic Control in a Patient Cohort with Poorly Controlled Type 1 Diabetes: A Randomized Open-Label Study. Journal of Diabetes Science and Technology, 2012, 6, 1392-1397.	1.3	12
197	Diabetes Technology: Markers, Monitoring, Assessment, and Control of Blood Glucose Fluctuations in Diabetes. Scientifica, 2012, 2012, 1-14.	0.6	25
199	Managing hypoglycemia in children: what the clinician needs to know before advising parents. Diabetes Management, 2012, 2, 503-512.	0.5	3
200	Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrology Dialysis Transplantation, 2012, 27, 1559-1568.	0.4	24
201	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, The, 2012, 379, 1498-1507.	6.3	304
202	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet, The, 2012, 379, 2270-2278.	6.3	138
203	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet, The, 2012, 380, 475-483.	6.3	310
204	Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 16-38.	1.8	926
205	Experience of hypoglycaemia and strategies used for its management by community-dwelling adults with diabetes mellitus: a systematic review. International Journal of Evidence-Based Healthcare, 2012, 10, 169-180.	0.1	21
206	Monotherapy with the onceâ€weekly GLPâ€1 analogue dulaglutide for 12â€∫weeks in patients with Typeâ€∫2 diabetes: doseâ€dependent effects on glycaemic control in a randomized, doubleâ€blind, placeboâ€controlled study. Diabetic Medicine, 2012, 29, 1260-1267.	1.2	87
207	Managing type 1 diabetes mellitus in pregnancyâ€"from planning to breastfeeding. Nature Reviews Endocrinology, 2012, 8, 659-667.	4.3	52
208	Update on Care of Children with Type 1 Diabetes. Advances in Pediatrics, 2012, 59, 303-327.	0.5	0
209	Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. Journal of Medical Economics, 2012, 15, 77-86.	1.0	75
210	Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Current Medical Research and Opinion, 2012, 28, 1947-1958.	0.9	53
211	Awareness is the key to preventing and/or minimizing drug-induced hypoglycaemia. Drugs and Therapy Perspectives, 2012, 28, 19-23.	0.3	0
212	5. The Impact of Hypoglycemia on the Developing Brain. Translational Endocrinology & Metabolism, 2012, , 137-159.	0.2	3
213	Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion, 2012, 28, 1465-1474.	0.9	40
214	Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opinion on Investigational Drugs, 2012, 21, 1463-1474.	1.9	12

#	Article	IF	CITATIONS
215	Decreased vascular endothelial growth factor response to acute hypoglycemia in type 2 diabetic patients with hypoglycemic coma. Cytokine, 2012, 57, 372-378.	1.4	3
216	Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients. Diabetes Research and Clinical Practice, 2012, 98, 119-124.	1.1	32
217	Accuracy of a portable glucose meter and of a Continuous Glucose Monitoring device used at home by patients with type 1 diabetes. Clinica Chimica Acta, 2012, 413, 312-318.	0.5	25
218	Hypoglycemia and Risk of Death in Critically III Patients. New England Journal of Medicine, 2012, 367, 1108-1118.	13.9	827
219	Food selection for treatment of hypoglycaemia in insulinâ€treated diabetes: what happens in real life?. Practical Diabetes, 2012, 29, 271-274.	0.1	5
220	A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocrine Disorders, 2012, 12, 10.	0.9	18
221	Insight into hypoglycemia in pediatric type 1 diabetes mellitus. International Journal of Pediatric Endocrinology (Springer), 2012, 2012, 19.	1.6	11
222	Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18â€week randomized, doubleâ€blind, placeboâ€controlled phase <scp>III</scp> trial with a 34â€week activeâ€controlled extension. Diabetes, Obesity and Metabolism, 2012, 14, 1145-1154.	2.2	51
223	The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. Journal of Diabetes and Its Complications, 2012, 26, 399-406.	1.2	90
224	Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes and Metabolism, 2012, 38, 550-557.	1.4	19
225	Hypoglycaemia in hospitalized non-diabetic older people. Review. European Geriatric Medicine, 2012, 3, 174-178.	1.2	4
226	Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus. Annals of Internal Medicine, 2012, 157, 336.	2.0	427
227	Evolution of Insulin Development: Focus on Key Parameters. Advances in Therapy, 2012, 29, 590-619.	1.3	53
228	Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1cvalue. Current Medical Research and Opinion, 2012, 28, 1281-1287.	0.9	16
229	Hypoglycemia in Non-Diabetic In-Patients: Clinical or Criminal?. PLoS ONE, 2012, 7, e40384.	1.1	53
230	Differences in the Acute Effects of Aerobic and Resistance Exercise in Subjects with Type 2 Diabetes: Results from the RAED2 Randomized Trial. PLoS ONE, 2012, 7, e49937.	1.1	39
231	Uncovering undetected hypoglycemic events. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012, 5, 57.	1.1	53
232	Severe Hypoglycemia in Patients with Diabetes. Diabetes and Metabolism Journal, 2012, 36, 273.	1.8	2

#	Article	IF	CITATIONS
233	Hypoglycemia in Hospitalized Patients Treated with Sulfonylureas. Pharmacotherapy, 2012, 32, 613-617.	1.2	62
234	Patient satisfaction and barriers to initiating realâ€time continuous glucose monitoring in early pregnancy in women with diabetes. Diabetic Medicine, 2012, 29, 272-277.	1.2	40
235	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to $2\hat{a} \in f$ years exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice, 2012, 66, 731-740.	0.8	36
236	The effect of bolus and food calculator <i>Diabetics</i> li>on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT. Pediatric Diabetes, 2012, 13, 534-539.	1.2	26
237	Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatric Diabetes, 2012, 13, 616-624.	1.2	19
238	Exploring the meaning of hypoglycaemia to communityâ€dwelling Singaporean Chinese adults living with type 2 diabetes mellitus. International Journal of Nursing Practice, 2012, 18, 252-259.	0.8	6
239	Dietary treatment of hypoglycaemia: should the Australian recommendation be increased?. Internal Medicine Journal, 2012, 42, 830-833.	0.5	10
240	Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparatorâ€controlled, doubleâ€blind study. Diabetes, Obesity and Metabolism, 2012, 14, 348-357.	2.2	97
241	Comparison between sitagliptin as addâ€on therapy to insulin and insulin doseâ€increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes, Obesity and Metabolism, 2012, 14, 795-802.	2.2	72
242	The impact of hypoglycaemia on quality of life and related patientâ€reported outcomes in Type 2 diabetes: a narrative review. Diabetic Medicine, 2012, 29, 293-302.	1.2	128
243	Severe hypoglycaemia and lateâ€life cognitive ability in older people with Typeâ€f2 diabetes: the Edinburgh Typeâ€f2 Diabetes Study. Diabetic Medicine, 2012, 29, 328-336.	1.2	83
244	Hypoglycaemia during pregnancy in women with Type 1 diabetes. Diabetic Medicine, 2012, 29, 558-566.	1.2	76
245	Multiple complications and frequent severe hypoglycaemia in †elderly†and †old†patients with Type†diabetes. Diabetic Medicine, 2012, 29, e176-9.	f] 1.2	66
246	Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes, 2013, 11, 90.	1.0	142
247	Hypoglycaemic symptoms and hypoglycaemia threshold in older people with diabetes-A patient perspective. Journal of Nutrition, Health and Aging, 2013, 17, 899-902.	1.5	17
248	Superior glycaemic control with onceâ€daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes, Obesity and Metabolism, 2013, 15, 826-832.	2.2	83
249	Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention. Current Diabetes Reports, 2013, 13, 669-678.	1.7	43
252	Which patients should be evaluated for blood glucose variability?. Diabetes, Obesity and Metabolism, 2013, 15, 9-12.	2.2	12

#	ARTICLE	IF	Citations
253	Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente concon diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de EndocrinologÃa y Nutrición. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 517.e1-517.e18.	0.8	22
254	The incidence of severe hypoglycaemia in pregnant women with type 1 diabetes mellitus can be reduced with unchanged HbA1c levels and pregnancy outcomes in a routine care setting. Diabetes Research and Clinical Practice, 2013, 101, 123-130.	1.1	24
255	Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-NaÃ-ve Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2536-2542.	4.3	141
256	Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control. American Journal of Medicine, 2013, 126, S21-S27.	0.6	30
257	Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations. American Journal of Transplantation, 2013, 13, 3236-3243.	2.6	55
258	Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. Journal of Medical Economics, 2013, 16, 468-478.	1.0	13
259	Confusing medical terms: disease that may or may not exist. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 617-621.	0.2	3
260	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia, 2013, 56, 2679-2687.	2.9	82
261	Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review. Cardiovascular Diabetology, 2013, 12, 135.	2.7	67
262	Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non-interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice. Diabetology and Metabolic Syndrome, 2013, 5, 43.	1.2	3
263	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. Journal of Diabetes and Its Complications, 2013, 27, 274-279.	1.2	16
264	A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200ÂU/mL Formulations of Ultra-Long-Acting Insulin Degludec. Clinical Drug Investigation, 2013, 33, 515-521.	1.1	81
265	Fasting glucose level is associated with nocturnal hypoglycemia in elderly male patients with type 2 diabetes. Aging Male, 2013, 16, 132-136.	0.9	12
266	Impaired hormonal counterregulation to biochemical hypoglycaemia does not explain the high incidence of severe hypoglycaemia during pregnancy in women with type 1 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 67-74.	0.6	4
267	A Glucose Model Based on Support Vector Regression for the Prediction of Hypoglycemic Events Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2013, 15, 634-643.	2.4	55
268	Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 123-130.	0.7	43
269	Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes, Obesity and Metabolism, 2013, 15, 130-135.	2.2	54
270	Insulin aspart has a shorter duration of action than human insulin over a wide doseâ€range. Diabetes, Obesity and Metabolism, 2013, 15, 77-83.	2.2	18

#	Article	IF	CITATIONS
271	Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Care, 2013, 36, 237-244.	4.3	162
272	Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. EndocrinologÃa Y Nutrición (English Edition), 2013, 60, 517.e1-517.e18.	0.5	4
273	Multicentre analysis of 178,992 type 2 diabetes patients revealed better metabolic control despite higher rates of hypertension, stroke, dementia and repeated inpatient care in patients with comorbid Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 687-692.	1.1	18
274	Historical data enhances safety supervision system performance in T1DM insulin therapy risk management. Computer Methods and Programs in Biomedicine, 2013, 109, 220-225.	2.6	8
275	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a doseâ€finding study. Diabetes, Obesity and Metabolism, 2013, 15, 403-409.	2.2	103
276	Insulin Degludec: A Novel Basal Insulin Analogue. Annals of Pharmacotherapy, 2013, 47, 269-277.	0.9	11
277	Hypoglycaemia in adults: When should it be raised? How can hypoglycaemia be confirmed in non-diabetic adults?. Annales D'Endocrinologie, 2013, 74, 168-173.	0.6	6
278	Revisiting hypoglycemia in diabetes. Osteopathic Family Physician, 2013, , .	0.2	0
279	Taspoglutide, a onceâ€weekly glucagonâ€like peptideâ€ $f1$ analogue, vs. insulin glargine titrated to target in patients with Typeâ€ $f2$ diabetes: an openâ€label randomized trial. Diabetic Medicine, 2013, 30, 109-113.	1.2	26
280	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1845-1859.	1.8	223
281	Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus. Drugs, 2013, 73, 575-593.	4.9	36
282	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus., 2013,, CD008143.		130
283	Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients. Current Medical Research and Opinion, 2013, 29, 101-107.	0.9	88
284	Hypoglycemia in Patients with Diabetes who Are Fasting for Laboratory Blood Tests: The Cape Girardeau Hypoglycemia En Route Prevention Program. Postgraduate Medicine, 2013, 125, 136-143.	0.9	8
285	Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus) Tj ETQq0 0 0 rgBT Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients. International Journal of Endocrinology, 2013, 2013, 1-6.	Overlock :	10 Tf 50 192 8
286	Hypoglycemia: The neglected complication. Indian Journal of Endocrinology and Metabolism, 2013, 17, 819.	0.2	180
287	Effect of Jeju Water on Blood Glucose Levels in Diabetic Patients: A Randomized Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	2
288	Diabetes and Driving. Diabetes Care, 2013, 36, S80-S85.	4.3	8

#	Article	IF	CITATIONS
289	Diabetes and Employment. Diabetes Care, 2013, 36, S93-S97.	4.3	6
290	Impact of Race on the Incidence of Hypoglycemia in Hospitalized Older Adults With Type 2 Diabetes. Clinical Diabetes, 2013, 31, 66-72.	1.2	5
291	Amelioration of Hypoglycemia Via Somatostatin Receptor Type 2 Antagonism in Recurrently Hypoglycemic Diabetic Rats. Diabetes, 2013, 62, 2215-2222.	0.3	34
292	Restoration of Self-Awareness of Hypoglycemia in Adults With Long-Standing Type 1 Diabetes. Diabetes Care, 2013, 36, 4063-4070.	4.3	46
293	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care, 2013, 36, 1384-1395.	4.3	1,125
294	Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 225-232.	2.2	13
295	A retrospective study on the incidence and risk factors of severe hypoglycemia in primary care. Family Practice, 2013, 30, 290-293.	0.8	29
296	Presence of Macroalbuminuria Predicts Severe Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 1283-1289.	4.3	49
297	Hypoglycaemiaâ€induced changes in regional brain volume and memory function. Diabetic Medicine, 2013, 30, e151-6.	1.2	31
298	Cross-cultural variation in symptom perception of hypoglycemia. Journal of Mid-Life Health, 2013, 4, 176.	0.4	8
299	Hypoglycaemia in anesthesiology practice: Diagnostic, preventive, and management strategies. Saudi Journal of Anaesthesia, 2013, 7, 447.	0.2	18
300	Insulin Pumpâ€"Long-Term Effects on Glycemic Control: An Observational Study at 10 Diabetes Clinics in Sweden. Diabetes Technology and Therapeutics, 2013, 15, 302-307.	2.4	32
302	Analysis of hypoglycemic events using negative binomial models. Pharmaceutical Statistics, 2013, 12, 233-242.	0.7	15
303	Retrospective analysis of safety and efficacy of insulinâ€toâ€liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced βâ€cell function. Journal of Diabetes Investigation, 2013, 4, 585-594.	1.1	25
304	Neonatal hyperglycemia and diminished long-term growth in very low birth weight preterm infants. Journal of Perinatology, 2013, 33, 882-886.	0.9	30
305	Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. Journal of Diabetes Science and Technology, 2013, 7, 562-578.	1.3	104
306	Professional Continuous Glucose Monitoring in Subjects with Type 1 Diabetes: Retrospective Hypoglycemia Detection. Journal of Diabetes Science and Technology, 2013, 7, 135-143.	1.3	21
307	Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes. Diabetes Care, 2013, 36, 522-528.	4.3	84

#	Article	IF	CITATIONS
308	Hypoglycemia-associated autonomic failure in diabetes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 295-307.	1.0	54
309	lves, Diabetes, and His "Exhausted Vein" of Composition. American Music, 2013, 31, 1.	0.1	0
310	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management, 2013, 9, 155.	1.0	135
311	Corrected QT Interval Prolongation during Severe Hypoglycemia without Hypokalemia in Patients with Type 2 Diabetes. Diabetes and Metabolism Journal, 2013, 37, 190.	1.8	18
312	Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals. Patient Preference and Adherence, 2013, 7, 285.	0.8	17
313	The Science of Hypoglycemia in Patients with Diabetes. Current Diabetes Reviews, 2013, 9, 195-208.	0.6	56
314	Diabetes mellitus: balancing blood glucose. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2013, 5, 388-393.	0.0	0
316	Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review. Clinical Epidemiology, 2014, 6, 287.	1.5	32
317	Patient safety and minimizing risk with insulin administration & Camp; ndash; role of insulin degludec. Drug, Healthcare and Patient Safety, 2014, 6, 55.	1.0	21
318	A Quadruply-Asymmetric Sigmoid to Describe the Insulin-Glucose Relationship during Intravenous Insulin Infusion. Journal of Healthcare Engineering, 2014, 5, 23-54.	1.1	3
320	HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia, 2014, 57, 2475-2484.	2.9	111
321	Evaluation of an Algorithm for Retrospective Hypoglycemia Detection Using Professional Continuous Glucose Monitoring Data. Journal of Diabetes Science and Technology, 2014, 8, 117-122.	1.3	17
322	A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. Diabetes Therapy, 2014, 5, 521-534.	1.2	10
323	Hypoglycemia and Retinal Cell Death. , 2014, , 627-636.		1
324	Hemoglobin A1c Levels and Risk of Severe Hypoglycemia in Children and Young Adults with Type 1 Diabetes from Germany and Austria: A Trend Analysis in a Cohort of 37,539 Patients between 1995 and 2012. PLoS Medicine, 2014, 11, e1001742.	3.9	118
325	Real-world Patient-reported Rates of Non-severe Hypoglycaemic Events in Germany. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 167-172.	0.6	22
326	Cardiovascular Autonomic Dysfunction Predicts Severe Hypoglycemia in Patients With Type 2 Diabetes: A 10-Year Follow-up Study. Diabetes Care, 2014, 37, 235-241.	4.3	38
327	Diabetes and Employment. Diabetes Care, 2014, 37, S112-S117.	4.3	28

#	ARTICLE	IF	CITATIONS
328	The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment. BioMed Research International, 2014, 2014, 1-7.	0.9	12
329	The Traditions and Risks of Fasting for Lipid Profiles in Patients with Diabetes. Postgraduate Medicine, 2014, 126, 98-107.	0.9	14
330	Diabetes and Driving. Diabetes Care, 2014, 37, S97-S103.	4.3	51
331	Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor?. Heart, 2014, 100, 21-27.	1.2	26
332	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care, 2014, 37, 2755-2762.	4.3	302
333	Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabetic Medicine, 2014, 31, 847-853.	1.2	90
334	The vexed question of hypoglycaemia and health economics. Diabetes, Obesity and Metabolism, 2014, 16, 289-293.	2.2	1
335	Efficacy and safety of onceâ€weekly glucagonâ€like peptide 1 receptor agonist albiglutide (<scp>HARMONY</scp> 1 trial): 52â€week primary endpoint results from a randomized, doubleâ€blind, placeboâ€controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes. Obesity and Metabolism. 2014. 16. 1257-1264.	2.2	85
336	Weight change upon onceâ€daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulinâ€naĀ ve individuals with type 2 diabetes: results from the DIET trial. Diabetes, Obesity and Metabolism, 2014, 16, 186-192.	2.2	14
337	Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatric Diabetes, 2014, 15, 27-33.	1.2	42
338	Realâ€ŧime continuous glucose monitoring as a tool to prevent severe hypoglycaemia in selected pregnant women with Type 1 diabetes ‰ an observational study. Diabetic Medicine, 2014, 31, 352-356.	1.2	25
339	Incidence of nonâ€severe hypoglycaemia and intensity of treatment among veterans with Type 2 diabetes in the USA: a prospective observational study. Diabetic Medicine, 2014, 31, 1524-1531.	1.2	6
340	Detection and treatment efficacy of hypoglycemic events in the everyday life of children younger than 7 yr. Pediatric Diabetes, 2014, 15, 34-40.	1.2	28
341	Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized openâ€label trial. Diabetes, Obesity and Metabolism, 2014, 16, 510-518.	2.2	11
342	HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care, 2014, 37, 2141-2148.	4.3	193
343	PO072 INTENSIVE INDIVIDUALIZED REINFORCEMENT EDUCATION IS IMPORTANT FOR THE PREVENTION OF HYPOGLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES. Diabetes Research and Clinical Practice, 2014, 106, S80-S81.	1.1	0
344	Association Between Severe Hypoglycemia, Adverse Macrovascular Events, and Inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care, 2014, 37, 3301-3308.	4.3	68
345	Selfâ€reported nonâ€severe hypoglycaemic events in Europe. Diabetic Medicine, 2014, 31, 92-101.	1.2	148

#	Article	IF	CITATIONS
346	Secondary diabetic ketoacidosis and severe hypoglycaemia in patients with established type 1 diabetes mellitus in China: a multicentre registration study. Diabetes/Metabolism Research and Reviews, 2014, 30, 497-504.	1.7	29
347	Hypoglycaemia in inpatients with diabetes on nasogastric feeding. Practical Diabetes, 2014, 31, 29-31.	0.1	2
348	Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention. Diabetes/Metabolism Research and Reviews, 2014, 30, 175-190.	1.7	36
349	Linagliptin for the treatment of Type 2 diabetes. Diabetes Management, 2014, 4, 85-101.	0.5	2
350	Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current Medical Research and Opinion, 2014, 30, 761-770.	0.9	5
351	Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain. Cardiovascular Endocrinology, 2014, 3, 85-91.	0.8	0
352	Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium. Acta Clinica Belgica, 2014, 69, 439-445.	0.5	17
353	Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 724-728.	0.7	41
354	Sunitinib-induced severe hypoglycemia in a diabetic patient. Journal of Oncology Pharmacy Practice, 2014, 20, 469-472.	0.5	14
355	Identifying and meeting the challenges of insulin therapy in type 2 diabetes. Journal of Multidisciplinary Healthcare, 2014, 7, 267.	1.1	58
356	Artifactual Hypoglycemia: An Old Term for a New Classification: Table 1. Diabetes Care, 2014, 37, e85-e86.	4.3	15
357	Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes/Metabolism Research and Reviews, 2014, 30, 104-119.	1.7	83
358	Inpatient Hypoglycemia: A Challenge That Must Be Addressed. Current Diabetes Reports, 2014, 14, 445.	1.7	20
359	Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus. Drugs and Aging, 2014, 31, 47-53.	1.3	28
360	Management of Type 1 Diabetes in Children and Adolescents. Indian Journal of Pediatrics, 2014, 81, 170-177.	0.3	9
361	Self-Reported Frequency and Impact of Hypoglycemic Events in Spain. Diabetes Therapy, 2014, 5, 155-168.	1.2	24
362	Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment. Clinical Pharmacokinetics, 2014, 53, 175-183.	1.6	63
363	Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment. Clinical Drug Investigation, 2014, 34, 127-133.	1.1	28

#	Article	IF	CITATIONS
364	Efficacy of structured education in patients with type 2 diabetes mellitus receiving insulin treatment (结构化教è,²å⁻¹æŽ¥å⊷èf°å²›ç´æ²»ç——çš"2型糖尿病æ,£è€…的效果). Journal of Diabetes, 201	4, 8; ⁸ 290-2	29 ² 8
365	Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes and Endocrinology, the, 2014, 2, 553-561.	5.5	83
366	Dipeptidyl Peptidase-4 Inhibitors Have Protective Effect on Cognitive Impairment in Aged Diabetic Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1122-1131.	1.7	80
367	CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European Journal of Clinical Pharmacology, 2014, 70, 421-428.	0.8	44
369	A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Diabetes Care, 2014, 37, 1476-1479.	4.3	14
370	Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Technology and Therapeutics, 2014, 16, 679-687.	2.4	74
371	Neurologic damage in hypoglycemia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 513-532.	1.0	28
373	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care, 2014, 37, 2317-2325.	4.3	186
374	Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care, 2014, 37, 2168-2176.	4.3	259
375	Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nature Reviews Endocrinology, 2014, 10, 711-722.	4.3	358
376	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.	4.3	236
377	A cross-sectional survey among patients and prescribers on insulin dosing irregularities and impact of mild (self-treated) hypoglycemia episodes in Spanish patients with type 2 diabetes as compared to other European patients. EndocrinologÃa Y Nutrición (English Edition), 2014, 61, 426-433.	0.5	3
378	Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care, 2014, 37, 2159-2167.	4.3	297
379	Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes. Diabetes Care, 2014, 37, 2746-2754.	4.3	133
380	Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet, The, 2014, 384, 1349-1357.	6.3	406
381	Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Quality of Life Research, 2014, 23, 2645-2650.	1.5	37
382	Insulin for the treatment of hyperkalemia: a double-edged sword?. CKJ: Clinical Kidney Journal, 2014, 7, 239-241.	1.4	22
383	High Hemoglobin <scp>A1c</scp> levels and glycemic variability increase risk of severe hypoglycemia in diabetic hemodialysis patients. Hemodialysis International, 2014, 18, 423-432.	0.4	16

#	Article	IF	CITATIONS
384	New Insulin Glargine 300 Units·mLâ^'1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mLâ^'1. Diabetes Care, 2015, 38, 637-643.	4.3	335
385	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care, 2014, 37, 3235-3243.	4.3	246
386	Perioperative intensive insulin therapy using an artificial endocrine pancreas with closed-loop glycemic control system: the effects of no hypoglycemia. American Journal of Surgery, 2014, 207, 935-941.	0.9	33
388	Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Diabetes Care, 2014, 37, 372-380.	4.3	16
389	Linagliptin treatment in subjects with type 2 diabetes with and without mildâ€toâ€moderate renal impairment. Diabetes, Obesity and Metabolism, 2014, 16, 560-568.	2.2	43
390	A cross-sectional survey among patients and prescribers on insulin dosing irregularities and impact of mild (self-treated) hypoglycemia episodes in Spanish patients with type 2 diabetes as compared to other European patients. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion. 2014. 61. 426-433.	0.8	8
392	Cognitive, behavioural and psychological barriers to the prevention of severe hypoglycaemia: A qualitative study of adults with type 1 diabetes. SAGE Open Medicine, 2014, 2, 205031211452744.	0.7	21
393	Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Experimental and Therapeutic Medicine, 2014, 8, 1191-1196.	0.8	8
394	Glycaemic variability and oxidative stress in children, with type 1 diabetes attending a summer camp. Anales De PediatrÃa (English Edition), 2014, 81, 174-180.	0.1	2
395	Effects of meal composition on postprandial incretin, glucose and insulin responses after surgical and medical weight loss. Obesity Science and Practice, 2015, 1, 104-109.	1.0	12
396	Fasterâ€acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes, Obesity and Metabolism, 2015, 17, 682-688.	2.2	121
397	Safety and efficacy of onceâ€weekly dulaglutide versus sitagliptin after 2 years in metforminâ€treated patients with type 2 diabetes (<scp>AWARD</scp> â€5): a randomized, phase <scp>III</scp> study. Diabetes, Obesity and Metabolism, 2015, 17, 849-858.	2.2	108
398	Patientâ€evel metaâ€analysis of the <scp>EDITION</scp> 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 859-867.	2.2	207
399	Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12â€month trial including 6â€month extension. Diabetes, Obesity and Metabolism, 2015, 17, 1142-1149.	2.2	105
400	Efficacy and safety of onceâ€weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with onceâ€daily insulin glargine in ⟨scp⟩J⟨/scp⟩apanese patients with type 2 diabetes: a randomized, openâ€label, phase ⟨scp⟩Ill⟨/scp⟩, nonâ€inferiority study. Diabetes, Obesity and Metabolism, 2015, 17, 994-1002.	2.2	66
401	A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocrine Journal, 2015, 62, 1101-1114.	0.7	25
402	Two Treatment Approaches for Human Regular U-500 Insulin in Patients With Type 2 Diabetes not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Titration-To-Target Clinical Trial. Endocrine Practice, 2015, 21, 782-794.	1.1	53
403	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology, 2015, 14, 116.	2.7	39

#	Article	IF	CITATIONS
404	The bitter taste of hypoglycemia. International Journal of Diabetes in Developing Countries, 2015, 35, 389-391.	0.3	0
405	Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders, 2015, 15, 57.	0.9	6
406	Factors that drive insulinâ€dosing decisions of diabetes care providers: a vignetteâ€based study in the Netherlands. Diabetic Medicine, 2015, 32, 69-77.	1.2	5
407	Self-reported frequency and impact of non-severe hypoglycemic events in insulin-treated diabetic patients in Denmark. Diabetes Management, 2015, 5, 67-78.	0.5	9
408	Is iatrogenic sleep disturbance worth the effort in TypeÂ1 diabetes?. Diabetic Medicine, 2015, 32, 984-986.	1.2	8
409	Fear of hypoglycaemia in adults with TypeÂ1 diabetes: results from Diabetes <scp>MILES</scp> – The Netherlands. Diabetic Medicine, 2015, 32, 1289-1296.	1.2	31
410	Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 868-877.	2.2	20
411	Efficacy and safety of onceâ€weekly glucagonâ€like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2015, 17, 1065-1074.	2.2	61
412	Glycaemic control and its associated factors in Chinese adults with type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2015, 31, 803-810.	1.7	23
414	Weightâ€based hypoglycaemia treatment protocol for adults with Type 1 diabetes: a randomized crossover clinical trial. Diabetic Medicine, 2015, 32, 1143-1148.	1.2	22
415	Diagnostic tools for postâ€gastric bypass hypoglycaemia. Obesity Reviews, 2015, 16, 843-856.	3.1	47
416	Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes. Diabetes and Metabolism Journal, 2015, 39, 154.	1.8	22
417	Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes. Diabetes and Metabolism Journal, 2015, 39, 498.	1.8	22
418	Predictors for Mild and Severe Hypoglycemia in Insulin-Treated Japanese Diabetic Patients. PLoS ONE, 2015, 10, e0130584.	1.1	8
419	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet, The, 2015, 385, 2057-2066.	6.3	180
420	Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia. Diabetes Care, 2015, 38, 1016-1029.	4.3	192
421	Hypoglycemic Accuracy and Improved Low Glucose Alerts of the Latest Dexcom G4 Platinum Continuous Glucose Monitoring System. Diabetes Technology and Therapeutics, 2015, 17, 548-554.	2.4	31
422	Effect of diabetic education on the knowledge, attitude and practices of diabetic patients towards prevention of hypoglycemia. Indian Journal of Endocrinology and Metabolism, 2015, 19, 383.	0.2	14

#	ARTICLE	IF	CITATIONS
423	Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients. Diabetes Care, 2015, 38, 1536-1543.	4.3	231
424	HypoDE. Journal of Diabetes Science and Technology, 2015, 9, 651-662.	1.3	17
425	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without) Tj ETQq0 0 0 and Metabolism, 2015, 17, 1056-1064.	rgBT /Ove 2.2	erlock 10 Tf 50 89
426	Update on strategies limiting iatrogenic hypoglycemia. Endocrine Connections, 2015, 4, R37-R45.	0.8	17
427	Evaluation of the treatment of diabetic ketoacidosis in the medical intensive care unit. American Journal of Health-System Pharmacy, 2015, 72, S177-S182.	0.5	5
428	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 2016, 39, 222-230.	4.3	158
429	Dogs Can Be Successfully Trained to Alert to Hypoglycemia Samples from Patients with Type 1 Diabetes. Diabetes Therapy, 2015, 6, 509-517.	1,2	51
430	Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes, 2015, 9, 15-22.	0.9	16
431	Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial. Diabetes Research and Clinical Practice, 2015, 107, 139-147.	1.1	63
432	New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulinâ€naà ve people with type 2 diabetes on oral glucoseâ€lowering drugs: a randomized controlled trial (EDITION 3). Diabetes, Obesity and Metabolism, 2015, 17, 386-394.	2.2	265
433	Blood Glucose Self-Monitoring Patterns in Mexican Americans: Further Lessons from the Starr County Border Health Initiative. Diabetes Technology and Therapeutics, 2015, 17, 105-111.	2.4	4
434	Escaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions. Journal of Diabetes Science and Technology, 2015, 9, 1148-1151.	1.3	22
435	Combining Information of Autonomic Modulation and CGM Measurements Enables Prediction and Improves Detection of Spontaneous Hypoglycemic Events. Journal of Diabetes Science and Technology, 2015, 9, 132-137.	1.3	28
436	Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years. Diabetes Technology and Therapeutics, 2015, 17, 21-28.	2.4	23
437	Self-reported frequency and impact of hypoglycaemic events in insulin-treated diabetic patients in Austria. Wiener Klinische Wochenschrift, 2015, 127, 36-44.	1.0	11
438	Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty. , 2015, 6, 156.		213
439	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care, 2015, 38, 2217-2225.	4.3	183
440	Preparation of pellets with controlled release of glucose as prevention of hypoglycaemia in paediatric patients. European Journal of Pharmaceutical Sciences, 2015, 75, 72-80.	1.9	14

#	Article	IF	CITATIONS
441	The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes. Drugs and Aging, 2015, 32, 583-590.	1.3	25
442	ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2015, 9, 139-142.	1.8	21
443	Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 2015, 38, 1592-1609.	4.3	119
444	Minimizing Hypoglycemia in Diabetes. Diabetes Care, 2015, 38, 1583-1591.	4.3	156
445	Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation. Diabetes Care, 2015, 38, 105-112.	4.3	41
446	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 2015, 373, 11-22.	13.9	1,492
447	Hypoglycemia in everyday life after gastric bypass and duodenal switch. European Journal of Endocrinology, 2015, 173, 91-100.	1.9	54
448	Risk factors associated with falls in elderly patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 898-902.	1.2	61
449	Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300ÂUÂmLâ^1 and Glargine 100ÂUÂmLâ^1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study. Diabetes Therapy, 2015, 6, 143-152.	1.2	23
450	Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study. Diabetes and Metabolism, 2015, 41, 116-125.	1.4	111
451	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective <scp>E</scp> uropean <scp>E</scp> xenatide (<scp>EUREXA</scp>) study. Diabetes, Obesity and Metabolism, 2015, 17, 689-698.	2.2	4
452	Non-ICU Hospital Care of Diabetes Mellitus in the Elderly Population. Current Diabetes Reports, 2015, 15, 26.	1.7	4
453	Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Using Insulin Analogs and Multiple Daily Injections in Pregnant Women with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Women's Health, 2015, 24, 237-249.	1.5	26
454	Pharmaceutical care of adolescents with diabetes mellitus type 1: the DIADEMA study, a randomized controlled trial. International Journal of Clinical Pharmacy, 2015, 37, 790-798.	1.0	19
455	Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatric Diabetes, 2015, 16, 164-176.	1.2	74
456	Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Journal of Medical Economics, 2015, 18, 56-68.	1.0	32
457	Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Research and Clinical Practice, 2015, 109, 226-232.	1.1	26
458	Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity and Metabolism, 2015, 17, 630-638.	2.2	51

#	Article	IF	Citations
459	Hypoglycemia-Associated Changes in the Electroencephalogram in Patients With Type 1 Diabetes and Normal Hypoglycemia Awareness or Unawareness. Diabetes, 2015, 64, 1760-1769.	0.3	33
460	Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy. Journal of Diabetes and Its Complications, 2015, 29, 395-399.	1.2	39
461	Oneâ€year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 <scp>U/ml</scp> compared with 100 <scp>U/ml</scp> in people with type 2 diabetes using basal plus mealâ€time insulin: the <scp>EDITION 1</scp> 12â€month randomized trial, including 6â€month extension. Diabetes, Obesity and Metabolism, 2015, 17, 835-842.	2.2	100
462	The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 2151-2157.	4.3	15
463	Comprehensive investigation of postmortem glucose levels in blood and body fluids with regard to the cause of death in forensic autopsy cases. Legal Medicine, 2015, 17, 475-482.	0.6	19
464	Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal, 2015, 170, 845-854.	1.2	93
465	Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia. BMC Endocrine Disorders, 2015, 15, 42.	0.9	11
466	Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of theÂTreatment-Related Impact Measure—Non-severe Hypoglycemic Events (TRIM-HYPO). Quality of Life Research, 2015, 24, 2971-2984.	1.5	9
467	Impact of Blood Glucose Reporting on Glycemic Variability in Veterans With Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1348-1349.	1.3	0
468	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care, 2015, 38, 2241-2249.	4.3	184
469	Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2015, 386, 964-973.	6.3	998
470	Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2015, 9, 1227-1235.	1.3	13
471	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, The, 2015, 351, h5364.	3.0	53
472	Development of an Educational Program on Prevention of Hypoglycemic Events Among Elderly Veterans With Type 2 Diabetes. The Diabetes Educator, 2015, 41, 690-697.	2.6	7
473	Semaglutide, a onceâ€weekly human GLPâ€1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology, 2015, 55, 497-504.	1.0	117
474	Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2â€year trial. Diabetes, Obesity and Metabolism, 2015, 17, 276-284.	2.2	9
475	Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and nonâ€diabetic patients. British Journal of Clinical Pharmacology, 2015, 79, 870-871.	1.1	14
476	Effect of Total Daily Dose on Efficacy, Dosing, and Safety of 2 Dose Titration Regimens of Human Regular U-500 Insulin in Severely Insulin-Resistant Patients with Type 2 Diabetes. Endocrine Practice, 2016, 22, 653-665.	1.1	24

#	Article	IF	Citations
477	Type 1 diabetes mellitus in children. Medicina, 2016, 52, 467-476.	0.0	0
478	Baseline-Corrected QT (QTc) Interval Is Associated with Prolongation of QTc during Severe Hypoglycemia in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2016, 40, 463.	1.8	11
479	rDNA insulin glargine U300 & Desity: a critical appraisal. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, Volume 9, 425-441.	1.1	10
480	Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes. Diabetes and Metabolism Journal, 2016, 40, 202.	1.8	60
481	Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2016, 40, 423.	1.8	46
482	Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy. Journal of Managed Care & Decialty Pharmacy, 2016, 22, 483-492.	0.5	12
483	PROGENS-HbA 1c study: safety and effectiveness of premixed recombinant human insulin (Gensulin) Tj ETQq0 C) 0 rgBT /C	verlock 10 Tf
484	Do dogs sense hypoglycaemia?. Diabetic Medicine, 2016, 33, 934-938.	1.2	9
485	Longâ€term outcome of insulin pump therapy: reduction of hypoglycaemia and impact on glycaemic control. Diabetic Medicine, 2016, 33, 1422-1426.	1.2	37
486	Switching from sulphonylurea to a sodiumâ€glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes, Obesity and Metabolism, 2016, 18, 628-632.	2.2	53
487	Openâ€label randomized nonâ€inferiority trial of a fixedâ€dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin. Diabetic Medicine, 2016, 33, 1084-1093.	1.2	3
488	Changes in insulin sensitivity and secretion after sleeve gastrectomy. British Journal of Surgery, 2016, 103, 242-248.	0.1	29
489	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitusâ€"the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008376.	0.8	30
490	Glycaemic Profiles of Children With Overweight and Obesity in Free-living Conditions in Association With Cardiometabolic Risk. Scientific Reports, 2016, 6, 31892.	1.6	12
492	Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	73
493	Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. Diabetes Care, 2016, 39, 502-510.	4.3	180
494	The Potential Cost Implications of Averting Severe Hypoglycemic Events Requiring Hospitalization in High-Risk Adults With Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2016, 10, 905-913.	1.3	27
495	Examining the Starting Dose of Glyburide in Gestational Diabetes. American Journal of Perinatology, 2016, 33, 214-220.	0.6	3

#	Article	IF	CITATIONS
496	Utilisation of emergency medical services for severe hypoglycaemia: An unrecognised health care burden. Journal of Diabetes and Its Complications, 2016, 30, 1081-1086.	1.2	25
497	Safety and metabolic impact of Ramadan fasting in children and adolescents with type 1 diabetes. Journal of Pediatric Endocrinology and Metabolism, 2016, 29, 533-41.	0.4	14
498	Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the United States (2005–2009). Journal of Medical Economics, 2016, 19, 852-857.	1.0	15
499	Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Research and Clinical Practice, 2016, 115, 31-38.	1.1	38
500	Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2016, 32, 1409-1416.	0.9	13
501	Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with typeÂ1 diabetes prone to severe hypoglycaemia: The HypoAna trial. Diabetes and Metabolism, 2016, 42, 249-255.	1.4	25
502	Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system. Journal of Artificial Organs, 2016, 19, 209-218.	0.4	25
503	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, 59, 2603-2612.	2.9	8
504	Regulatory Forum Opinion Piece. Toxicologic Pathology, 2016, 44, 931-946.	0.9	4
505	Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 121, 192-203.	1.1	52
506	Randomized, doubleâ€blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: ⟨scp⟩IMAGINE⟨/scp⟩ 3. Diabetes, Obesity and Metabolism, 2016, 18, 1081-1088.	2.2	42
507	Pancreatic islet cell transplantation as a treatment for brittle type 1 diabetes: A case report and review of the literature. Journal of Taibah University Medical Sciences, 2016, 11, 395-400.	0.5	3
508	Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 977-987.	1.5	32
509	Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in people with Type 1 diabetes mellitus. Diabetic Medicine, 2016, 33, 77-83.	1.2	16
510	Hypoglycaemia in adults with insulinâ€treated diabetes in the <scp>UK</scp> : selfâ€reported frequency and effects. Diabetic Medicine, 2016, 33, 1125-1132.	1.2	45
511	Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36â€week, randomized, doubleâ€blind, parallelâ€group trial. Journal of Diabetes Investigation, 2016, 7, 565-573.	1.1	50
512	Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucoseâ€lowering effects. Journal of Diabetes Investigation, 2016, 7, 574-580.	1.1	8
513	A 1â€year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study). Journal of Diabetes Investigation, 2016, 7, 703-710.	1.1	19

#	Article	IF	CITATIONS
514	Onceâ€weekly glucagonâ€like peptideâ€l receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with onceâ€daily liraglutide in <scp>J</scp> apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase <scp>III</scp> study. Diabetes, Obesity and Metabolism, 2016, 18, 249-257.	2.2	50
515	New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (<scp>EDITION JP</scp> 1). Diabetes, Obesity and Metabolism, 2016, 18, 375-383.	2.2	76
516	Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes, Obesity and Metabolism, 2016, 18, 463-474.	2.2	12
517	Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulinâ€treated type 1 and type 2 diabetes: the global <scp>HAT</scp> study. Diabetes, Obesity and Metabolism, 2016, 18, 907-915.	2.2	203
518	Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised) Tj ETQq0 0 (OngBT/Ov	venboock 10 Tf !
519	IN CONTROL of type 1 diabetes, despite hypoglycaemia unawareness. Lancet Diabetes and Endocrinology,the, 2016, 4, 874-875.	5.5	3
520	Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet, The, 2016, 388, 2254-2263.	6.3	723
521	Efficacy and safety of liraglutide compared to sulphonylurea during <scp>R</scp> amadan in patients with type 2 diabetes (<scp>LIRAâ€R</scp> amadan): a randomized trial. Diabetes, Obesity and Metabolism, 2016, 18, 1025-1033.	2.2	39
522	Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime) Tj ETQq0 in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study. Medicina	0.0 orgBT	Overlock 10 O
	ClÃnica (English Edition), 2016, 146, 239-246.		
523	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77.	1.7	93
523 524	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current	1.7	93
	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7,		93 7
524	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7, 270-275. Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in	1.1	7
524 525	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7, 270-275. Clucose: archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in Medicine, 2016, 10, 1153-1166. RSSDI clinical practice recommendations for management of In-hospital hyperglycaemia—2016.	0.6	7
524 525 526	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7, 270-275. Clucose: archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in Medicine, 2016, 10, 1153-1166. RSSDI clinical practice recommendations for management of In-hospital hyperglycaemia—2016. International Journal of Diabetes in Developing Countries, 2016, 36, 1-21. Prognosis of alcohol-associated lactic acidosis in critically ill patients: an 8-year study. Scientific	1.1 0.6 0.3	7 10 6
524 525 526 527	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7, 270-275. Clucose: archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in Medicine, 2016, 10, 1153-1166. RSSDI clinical practice recommendations for management of In-hospital hyperglycaemia—2016. International Journal of Diabetes in Developing Countries, 2016, 36, 1-21. Prognosis of alcohol-associated lactic acidosis in critically ill patients: an 8-year study. Scientific Reports, 2016, 6, 35368. Bacterial meningitis in diabetes patients: a population-based prospective study. Scientific Reports, 2016,	1.1 0.6 0.3	7 10 6
524 525 526 527	Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 77. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with typeÂ1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation, 2016, 7, 270-275. Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in Medicine, 2016, 10, 1153-1166. RSSDI clinical practice recommendations for management of In-hospital hyperglycaemia—2016. International Journal of Diabetes in Developing Countries, 2016, 36, 1-21. Prognosis of alcohol-associated lactic acidosis in critically ill patients: an 8-year study. Scientific Reports, 2016, 6, 35368. Bacterial meningitis in diabetes patients: a population-based prospective study. Scientific Reports, 2016, 6, 36996.	1.1 0.6 0.3	7 10 6 6 23

#	Article	IF	CITATIONS
533	EpidemiologÃa y control clÃnico de la diabetes mellitus tipo 2 y sus comorbilidades en España (estudio) Tj ETQq	0 <u>0 0</u> rgB1	7 Overlock 10
534	Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. BMJ Open Diabetes Research and Care, 2016, 4, e000192.	1.2	13
535	Self-reported hypoglycaemia in patients with type 2 diabetes treated with insulin in the Hoorn Diabetes Care System Cohort, the Netherlands: a prospective cohort study. BMJ Open, 2016, 6, e012793.	0.8	7
536	A grid-based tool for optimal performance monitoring of a glycemic regulator. Optimal Control Applications and Methods, 2016, 37, 1103-1121.	1.3	2
537	Differences in Anthropometric and Metabolic Parameters Between Subjects with Hypoglycaemia and Subjects with Euglycaemia After an Oral Glucose Tolerance Test Six Months After Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2016, 26, 2747-2755.	1.1	3
538	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 2016, 39, 1501-1509.	4.3	126
539	Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2016, 10, 1251-1258.	1.3	22
541	Managing hypoglycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 413-430.	2.2	42
542	Insulin degludec versus insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 trial. Diabetology International, 2016, 7, 141-147.	0.7	6
543	Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. Pediatric Diabetes, 2016, 17, 642-649.	1.2	14
544	<scp>AMG 151 (<scp>ARRYâ€403</scp>), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 191-195.</scp>	2.2	36
545	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52Âweek primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia, 2016, 59, 266-274.	2.9	85
546	A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care, 2016, 39, 448-454.	4.3	31
547	Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery. Obesity Research and Clinical Practice, 2016, 10, 1-14.	0.8	56
548	High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: A multicenter cohort study on 215,932 patients from the German/Austrian diabetes registry. Diabetes Research and Clinical Practice, 2016, 112, 73-81.	1.1	37
549	Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine, 2016, 52, 516-526.	1.1	63
550	Medical Practice Variations in Diabetes Mellitus., 2016,, 323-359.		1
551	New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (<scp>EDITION JP</scp> 2). Diabetes, Obesity and Metabolism, 2016, 18, 366-374.	2.2	99

#	Article	IF	CITATIONS
552	Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. Diabetes Therapy, 2016, 7, 45-60.	1.2	116
553	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 252-257.	2.4	42
554	Incidence and risk factors of hypoglycemia among Type 2 diabetic patients in a South Indian hospital. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, S22-S25.	1.8	6
555	Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime) Tj ETQq1 in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study. Medicina	1 0.78431 0.3	.4 rgBT /Ove 14
	ClÃnica, 2016, 146, 239-246.		
556	Professional Practice Committee. Diabetes Care, 2016, 39, S3-S3.	4.3	2
557	Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. Journal of Pain and Symptom Management, 2016, 51, 79-87.e1.	0.6	23
558	Hypoglycemia and Hypoglycemic Syndromes. , 2016, , 816-838.e8.		2
559	Type 2 Diabetes., 0,,.		4
560	Glycated hemoglobin A1c as a risk factor for severe hypoglycemia in pediatric type 1 diabetes. Pediatric Diabetes, 2017, 18, 51-58.	1.2	49
561	Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial. Metabolism: Clinical and Experimental, 2017, 69, 148-156.	1.5	13
562	Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies. Diabetes/Metabolism Research and Reviews, 2017, 33, e2883.	1.7	9
563	Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes and Endocrinology, the, 2017, 5, 261-270.	5.5	120
564	Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care, 2017, 40, 554-560.	4.3	99
565	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice, 2017, 126, 230-239.	1.1	22
566	Self-reported regular alcohol consumption in adolescents and emerging adults with type 1 diabetes: A neglected risk factor for diabetic ketoacidosis? Multicenter analysis of 29 630 patients from the DPV registry. Pediatric Diabetes, 2017, 18, 817-823.	1.2	33
567	Review of insulinâ€associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. Journal of Diabetes Investigation, 2017, 8, 635-645.	1.1	14
568	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in <scp>E</scp> urope and the <scp>USA</scp> . Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	2.2	100
569	A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus. Drugs and Aging, 2017, 34, 29-38.	1.3	30

#	Article	IF	CITATIONS
570	Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes, 2017, 18, 903-910.	1.2	58
571	Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. Clinical Drug Investigation, 2017, 37, 503-509.	1.1	28
572	Use of Flash Glucose-Sensing Technology for 12Âmonths as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. Diabetes Therapy, 2017, 8, 573-586.	1.2	141
573	Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes, Obesity and Metabolism, 2017, 19, 1562-1569.	2.2	3
574	Hyperglycemia., 0,, 225-230.		1
576	Accuracy Evaluation of 19 Blood Glucose Monitoring Systems Manufactured in the Asia-Pacific Region: A Multicenter Study. Journal of Diabetes Science and Technology, 2017, 11, 953-965.	1.3	11
577	Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism, 2017, 19, 1425-1435.	2.2	39
578	Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry. Diabetes Research and Clinical Practice, 2017, 129, 52-58.	1.1	15
579	Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION) Tj ETQq 446-452.	0	Qyerlock 10
580	Jump starting shared medical appointments for diabetes with weight management: Rationale and design of a randomized controlled trial. Contemporary Clinical Trials, 2017, 58, 1-12.	0.8	11
581	Hypoglycaemia and brief interventions in the emergency department – A systematic review. International Emergency Nursing, 2017, 34, 43-50.	0.6	2
582	A Systematic Review and Meta-analysis of Executive Function Performance in Type 1 Diabetes Mellitus. Psychosomatic Medicine, 2017, 79, 684-696.	1.3	49
583	Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naÃ-ve people with type 2Âdiabetes: 12-month results from the EDITION 3 trial. Diabetes and Metabolism, 2017, 43, 351-358.	1.4	46
584	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia, 2017, 60, 1390-1399.	2.9	68
585	Excessive daytime somnolence is associated with hypoglycemia in adult Latinos with type 2 diabetes mellitus. Sleep Medicine, 2017, 36, 6-9.	0.8	6
586	Acute Hypoglycemia in Healthy Humans Impairs Insulin-Stimulated Glucose Uptake and Glycogen Synthase in Skeletal Muscle: A Randomized Clinical Study. Diabetes, 2017, 66, 2483-2494.	0.3	7
587	Active Subjects with Autoimmune Type 1 Diabetes have Better Metabolic Profiles than Sedentary Controls. Cell Transplantation, 2017, 26, 23-32.	1.2	31
588	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics, 2017, 19, 391-399.	2.4	45

#	Article	IF	Citations
589	Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters. Diabetes Technology and Therapeutics, 2017, 19, S-16-S-26.	2.4	130
590	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	1.1	53
591	Pathophysiology and Management of Hypoglycemiain End-Stage Renal Disease Patients: A Review. Endocrine Practice, 2017, 23, 353-362.	1.1	35
592	Placeboâ€controlled, randomized trial of the addition of onceâ€weekly glucagonâ€like peptideâ€1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (<scp>AWARD</scp> â€9). Diabetes, Obesity and Metabolism, 2017, 19, 1024-1031.	2.2	98
593	Metrics for glycaemic control $\hat{a}\in$ " from HbA1c to continuous glucose monitoring. Nature Reviews Endocrinology, 2017, 13, 425-436.	4.3	185
594	Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Therapy, 2017, 8, 55-73.	1.2	433
595	Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care, 2017, 40, 832-838.	4.3	262
596	Glucose concentrations of less than 3.0Âmmol/l (54Âmg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes. Diabetologia, 2017, 60, 3-6.	2.9	99
597	Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 1358.	3.8	320
598	Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8. Diabetes Technology and Therapeutics, 2017, 19, 463-470.	2.4	4
599	Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Internal Medicine, 2017, 177, 1461.	2.6	105
600	Hypoglycemia awareness among insulin-treated patients with diabetes in Malaysia: A cohort subanalysis of the HAT study. Diabetes Research and Clinical Practice, 2017, 133, 40-49.	1.1	15
601	Downregulation of Insulin Sensitivity After Oral Glucose Administration: Evidence for the Anti-Incretin Effect. Diabetes, 2017, 66, 2756-2763.	0.3	24
602	Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucoseâ€dependent insulinotropic polypeptide/glucagonâ€like peptideâ€1 agonist <scp>RG</scp> 7697 in people with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 1436-1445.	2.2	63
604	Self-reported Hypoglycaemic Events in $2\hat{a}$ \in %430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 592-597.	0.6	11
605	Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. Journal of Diabetes and Its Complications, 2017, 31, 1620-1623.	1.2	2
606	TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. Canadian Journal of Diabetes, 2017, 41, 478-484.	0.4	29
607	Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Research and Clinical Practice, 2017, 134, 17-28.	1.1	40

#	Article	IF	CITATIONS
608	Hypoglycemia Patients and Transport by EMS in Alameda County, 2013–15. Prehospital Emergency Care, 2017, 21, 767-772.	1.0	22
609	Complete Neurologic Recovery From Extreme Hypoglycemia Secondary to Cardiogenic Liver Failure. A & A Case Reports, 2017, 9, 236-238.	0.7	1
610	Association Between Hypoglycemia and theÂBurden ofÂComorbidities in Hospitalized Vulnerable Older Diabetic Patients: A Cross-Sectional, Population-Based Study. Diabetes Therapy, 2017, 8, 1405-1413.	1.2	16
611	Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine. Diabetes Therapy, 2017, 8, 545-554.	1.2	6
612	An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin. Diabetes Therapy, 2017, 8, 767-780.	1.2	5
613	Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 33.	3.8	179
614	Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 45.	3.8	199
615	Continuous Subcutaneous Insulin Infusion for Adults with Type 1 Diabetes Mellitus. American Journal of Medicine, 2017, 130, 1255-1258.e1.	0.6	0
616	The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. Diabetes Research and Clinical Practice, 2017, 123, 143-148.	1,1	4
617	Comparison between a novel and conventional artificial pancreas for perioperative glycemic control using a closed-loop system. Journal of Artificial Organs, 2017, 20, 84-90.	0.4	13
618	Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulinâ€experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Panâ€Asian, treatâ€toâ€target Phase 3 Trial. Journal of Diabetes, 2017, 9, 243-247.	0.8	11
619	Comment on "Costs associated with emergency care and hospitalization for severe hypoglycemia― Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 86-87.	1.1	0
620	Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Na \tilde{A} -ve People With Type 2 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 263-269.	1.3	9
621	Female sex, young age, northern German residence, hypoglycemia and disabling diabetes complications are associated with depressed mood in the WHO-5 questionnaire – A multicenter DPV study among 17,563 adult patients with type 2 diabetes. Journal of Affective Disorders, 2017, 208, 384-391.	2.0	19
622	Glucagonâ€ike peptideâ€1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: <scp>a</scp> systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2017, 19, 228-238.	2.2	75
623	Pharmacological properties of fasterâ€acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, doubleâ€blind, crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 208-215.	2.2	67
624	Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2017, 56, 649-660.	1.6	54
625	Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2017, 40, 155-157.	4.3	488

#	Article	IF	CITATIONS
626	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 273-284.	1.1	25
627	Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety. Endocrinology and Metabolism, 2017, 32, 265.	1.3	12
628	Coexisting Diabetes Mellitus in Neurosurgical Patients. , 2017, , 713-731.		0
629	Patients with glycogen storage diseases undergoing anesthesia: a case series. BMC Anesthesiology, 2017, 17, 134.	0.7	11
630	Type 1 diabetes genomeâ€wide association studies: not to be lost in translation. Clinical and Translational Immunology, 2017, 6, e162.	1.7	70
631	Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 711-720.	0.7	3
632	Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Current Medical Research and Opinion, 2018, 34, 981-994.	0.9	16
633	Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study. Diabetology International, 2018, 9, 189-195.	0.7	2
634	An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study. BMC Endocrine Disorders, 2018, 18, 9.	0.9	5
635	Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fastâ€acting insulin aspart compared with insulin aspart. Diabetes, Obesity and Metabolism, 2018, 20, 1615-1622.	2.2	28
636	Islet Cell or Pancreas Transplantation. Endocrinology, 2018, , 1-40.	0.1	1
637	Glucose control and autonomic response during acute stress in youth with type 1 diabetes: A pilot study. Pediatric Diabetes, 2018, 19, 1020-1024.	1.2	3
638	Impact of Hypoglycemia on Brain Metabolism During Diabetes. Molecular Neurobiology, 2018, 55, 9075-9088.	1.9	47
639	Sodiumâ€glucose coâ€transporterâ€2 inhibitors as addâ€on therapy to insulin for type 1 diabetes mellitus: Systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 1755-1761.	2.2	66
640	Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Research and Clinical Practice, 2018, 138, 35-43.	1.1	19
641	Impact of the severity of hypoglycemia on health - Related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 451-457.	1.2	19
642	Severity of hypoglycaemia and healthâ€related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe. Endocrinology, Diabetes and Metabolism, 2018, 1, e00011.	1.0	10
643	Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. Journal of Diabetes Science and Technology, 2018, 12, 680-686.	1.3	13

#	Article	IF	CITATIONS
644	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>postâ€hoc</i> analysis of the AWARDâ€2, â€4 and â€5 Trials. Diabetes, Obesity and Metabolism, 2 20, 1490-1498.	01:82	40
645	Mindfulness and fear of hypoglycaemia in parents of children with Type 1 diabetes: results from Diabetes <scp>MILES</scp> Youth – The Netherlands. Diabetic Medicine, 2018, 35, 650-657.	1.2	18
646	Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabetic Medicine, 2018, 35, 588-594.	1.2	122
648	Microvascular Outcomes of Pediatric-Onset Type 1 Diabetes Mellitus: A Single-Center Observational Case Reviews in Sana'a, Yemen. Clinical Medicine Insights: Endocrinology and Diabetes, 2018, 11, 117955141774921.	1.0	0
649	Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia, 2018, 61, 539-550.	2.9	124
650	Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes and Metabolism, 2018, 44, 333-340.	1.4	5
651	The Bidirectional Association Between Depression and Severe Hypoglycemic and Hyperglycemic Events in Type 1 Diabetes. Diabetes Care, 2018, 41, 446-452.	4.3	40
652	Association of hypoglycaemia severity with clinical, patientâ€reported and economic outcomes in US patients with type 2 diabetes using basal insulin. Diabetes, Obesity and Metabolism, 2018, 20, 1156-1165.	2.2	13
653	Abnormally low Bispectral index and severe hypoglycemia during maintenance of and recovery from general anesthesia in diabetic retinopathy surgery: two case reports. BMC Anesthesiology, 2018, 18, 45.	0.7	6
654	Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities. Pharmacoeconomics, 2018, 36, 523-532.	1.7	2
655	A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open, 2018, 8, e019864.	0.8	18
656	The application of simple metrics in the assessment of glycaemic variability. Diabetes and Metabolism, 2018, 44, 313-319.	1.4	75
657	Effect of Insulin Analogs on Frequency of Non–Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose—The HypoAna Trial. Diabetes Technology and Therapeutics, 2018, 20, 247-256.	2.4	17
658	Acidosis mediates recurrent hypoglycemia-induced increase in ischemic brain injury in treated diabetic rats. Neuropharmacology, 2018, 135, 192-201.	2.0	4
659	Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65ÂYears, ≥ 65ÂYears): A Post Hoc Analysis from the ELEMENT-2 Study. Diabetes Therapy,	2 01 8, 9, 8	32 5 -837.
660	Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. Diabetes Therapy, 2018, 9, 727-741.	1.2	5
661	Fastâ€acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucoseâ€lowering effect relative to insulin aspart. Journal of Diabetes Investigation, 2018, 9, 303-310.	1.1	15
662	The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study. Canadian Journal of Diabetes, 2018, 42, 11-17.	0.4	28

#	Article	IF	CITATIONS
663	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (<scp>EDITION</scp> 4). Diabetes, Obesity and Metabolism, 2018, 20, 121-128.	2.2	34
664	The role of structured education in the management of hypoglycaemia. Diabetologia, 2018, 61, 751-760.	2.9	49
665	Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twiceâ€daily basal insulin to onceâ€daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2) Tj ETQc	1 0212 0 rgB1	「 / Øverlock I
666	Safety and efficacy of the combination of the glucagonâ€like peptideâ€1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: ⟨i⟩Postâ€hoc⟨/i⟩ analysis of a randomized, 52â€week, openâ€label, parallelâ€group trial. Journal of Diabetes Investigation, 2018, 9, 831-839.	1.1	4
667	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <scp>U/mL</scp> vs glargine 100 <scp>U/mL</scp> : 1â€year patientâ€level metaâ€analysis of the <scp>EDITION</scp> clinical studies in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 541-548.	2.2	69
668	Hypoglycemia in sulfonylureaâ€treated <i>KCNJ11</i> â€neonatal diabetes: Mildâ€moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures. Pediatric Diabetes, 2018, 19, 393-397.	1.2	21
669	Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes—a clinical perspective. Annals of Translational Medicine, 2018, 6, S111-S111.	0.7	1
670	A Wearable, Low-cost Hand Tremor Sensor for Detecting Hypoglycemic Events in Diabetic Patients. , 2018, , .		6
671	An Intervention by a Patient-Designed Do-It-Yourself Mobile Device App Reduces HbA1c in Children and Adolescents with Type 1 Diabetes: A Randomized Double-Crossover Study. Diabetes Technology and Therapeutics, 2018, 20, 797-805.	2.4	38
672	Hypoglycemia incidence and awareness among insulin-treated patients with diabetes: the HAT study in Brazil. Diabetology and Metabolic Syndrome, 2018, 10, 83.	1.2	38
673	Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan. BMJ Open, 2018, 8, e024909.	0.8	8
674	KNOWLEDGE ON HYPOGLYCEMIA AMONG PATIENTS WITH DIABETES MELLITUS Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 236.	0.3	4
675	Efficacy and tolerability of novel triple combination therapy in drug-naÃ-ve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. BMJ Open, 2018, 8, e022448.	0.8	5
676	Postprandial Hyperglycemia Is Associated With White Matter Hyperintensity and Brain Atrophy in Older Patients With Type 2 Diabetes Mellitus. Frontiers in Aging Neuroscience, 2018, 10, 273.	1.7	29
677	Reliability and validity of the Chinese version of the new fear of hypoglycemia scale: FH-15. International Journal of Nursing Sciences, 2018, 5, 343-351.	0.5	8
678	Ethnic variations in the risk of hypoglycaemia among people with Type 2 diabetes prescribed insulins and/or sulfonylureas: a historical cohort study using general practiceâ€recorded data. Diabetic Medicine, 2018, 35, 1707-1715.	1.2	2
679	A Randomized Controlled Trial to Compare the Effect of Peanuts and Almonds on the Cardio-Metabolic and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus. Nutrients, 2018, 10, 1565.	1.7	54
680	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. International Journal of Endocrinology, 2018, 2018, 1-6.	0.6	6

#	Article	IF	CITATIONS
681	Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. Diabetes Technology and Therapeutics, 2018, 20, 758-766.	2.4	7
682	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy, 2018, 9, 2043-2053.	1.2	6
683	Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. Diabetes and Metabolism Journal, 2018, 42, 3.	1.8	25
684	Hypoglycemia and cognitive function in diabetic patients. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 893-896.	1.8	16
685	Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS ONE, 2018, 13, e0194801.	1.1	29
686	Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. Journal of Diabetes Research, 2018, 2018, 1-28.	1.0	25
687	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. Current Diabetes Reports, 2018, 18, 53.	1.7	127
688	A Minimal Model Approach for Analyzing Continuous Glucose Monitoring in Type 2 Diabetes. Frontiers in Physiology, 2018, 9, 673.	1.3	7
690	Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatric Diabetes, 2018, 19, 1294-1301.	1.2	83
691	The Effect of Low-Carbohydrate Diet on Glycemic Control in Patients with Type 2 Diabetes Mellitus. Nutrients, 2018, 10, 661.	1.7	58
692	Hypoglycaemia in diabetes: do we think enough of the cause? An observational study on prevalence and causes of hypoglycaemia among patients with type 2 diabetes in an out-patient setting in Sri Lanka. BMC Endocrine Disorders, 2018, 18, 35.	0.9	6
693	Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2018, 20, 531-540.	2.4	69
694	HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care. JRSM Open, 2018, 9, 205427041877366.	0.2	1
695	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mildâ€toâ€moderate renal impairment. Diabetes, Obesity and Metabolism, 2018, 20, 2860-2868.	2.2	20
696	Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial. Pediatric Diabetes, 2018, 19, 1263-1270.	1.2	8
697	Risk of hypoglycemia in youth with type 2 diabetes on insulin. Journal of Pediatric Endocrinology and Metabolism, 2018, 31, 625-630.	0.4	4
698	Regional variations in definitions and rates of hypoglycaemia: findings from the global <scp>HAT</scp> observational study of 27 585 people with Type 1 and insulinâ€treated Type 2 diabetes mellitus. Diabetic Medicine, 2018, 35, 1232-1241.	1.2	8
699	Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology. Current Diabetes Reports, 2018, 18, 83.	1.7	24

#	ARTICLE	IF	CITATIONS
700	Regional differences in type 2 diabetes treatment and outcomes in Germanyâ€"An analysis of the German DPV and DIVE registries. Diabetes/Metabolism Research and Reviews, 2018, 34, e3049.	1.7	8
701	Effects of starvation and short-term refeeding on gastric emptying and postprandial blood glucose regulation in adolescent girls with anorexia nervosa. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E565-E573.	1.8	33
702	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2018, 20, 603-612.	2.4	28
703	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care, 2018, 41, 1783-1791.	4.3	82
704	Improved glycaemic control and treatment satisfaction with a simple wearable 3â€day insulin delivery device among people with Type 2 diabetes. Diabetic Medicine, 2018, 35, 1448-1456.	1.2	15
705	Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12â€month comparison by concomitant sulphonylurea and/or glinide use. Diabetes, Obesity and Metabolism, 2018, 20, 2541-2550.	2.2	3
706	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care, 2018, 41, 1672-1680.	4.3	44
707	Exposure to hypoglycemia and risk of stroke. Annals of the New York Academy of Sciences, 2018, 1431, 25-34.	1.8	34
709	Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta-analysis of randomised controlled trials. Journal of Telemedicine and Telecare, 2019, 25, 402-413.	1.4	39
710	Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. Cardiovascular Diabetology, 2019, 18, 103.	2.7	51
711	Incidence of hypoglycaemia in the South African population with diabetes: results from the IDMPS Wave 7 study. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2019, 24, 58-64.	0.4	4
712	Fasting during the holy month of Ramadan among older children and adolescents with type 1 diabetes in Kuwait. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 843-849.	0.4	9
713	Longâ€term efficacy and safety of combined insulin and glucagonâ€like peptideâ€1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
714	The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. BMC Endocrine Disorders, 2019, 19, 78.	0.9	10
715	Accuracy of the point-of-care glucose meter for use in calves. Journal of Veterinary Medical Science, 2019, 81, 1301-1304.	0.3	4
716	An on-line support tool to reduce exercise-related hypoglycaemia and improve confidence to exercise in type 1 diabetes. Journal of Diabetes and Its Complications, 2019, 33, 682-689.	1.2	5
717	Low fasting glucose and future risks of major adverse outcomes in people without baseline diabetes or cardiovascular disease: a systematic review and meta-analysis. BMJ Open, 2019, 9, e026010.	0.8	14
718	Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. Diabetes and Vascular Disease Research, 2019, 16, 385-395.	0.9	47

#	Article	IF	CITATIONS
719	Magnetic resonance imaging changes in a 69-year old man with hypoglycemia induced brain injury: case report and literature review. Pan African Medical Journal, 2019, 32, 131.	0.3	4
720	Survey on hypoglycemia among insulin-treated patients with diabetes: The Colombian International Operations Hypoglycemia Assessment Tool population. Biomedica, 2019, 39, 576-586.	0.3	2
721	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. Journal of Primary Care and Community Health, 2019, 10, 215013271988063.	1.0	14
722	Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naA ve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. Endocrine lournal, 2019, 66, 745-752.	0.7	10
723	Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances. Clinical Therapeutics, 2019, 41, 2073-2089.e6.	1.1	12
724	Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 845-855.	1.8	30
725	Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures. Obesity Facts, 2019, 12, 397-406.	1.6	26
726	Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life. EndocrinologÃa Diabetes Y Nutrición (English) Tj ETQq1	1 @.1 78431	45rgBT/Ove
727	Blockade of Acid-Sensing Ion Channels Attenuates Recurrent Hypoglycemia-Induced Potentiation of Ischemic Brain Damage in Treated Diabetic Rats. NeuroMolecular Medicine, 2019, 21, 454-466.	1.8	4
728	Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries. Advances in Therapy, 2019, 36, 1628-1641.	1.3	5
729	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care, 2019, 42, 1464-1472.	4.3	5
730	Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 462-472.	5.5	84
731	Qualitative analysis of patient responses to the ABCD FreeStyle Libre audit questionnaire. Practical Diabetes, 2019, 36, 45-50.	0.1	15
732	Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technology and Therapeutics, 2019, 21, 155-158.	2.4	48
733	Better glycaemic control with BioChaperone glargine lispro coâ€formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	2.2	5
734	Accuracy of a composite event definition for hypoglycemia. Pharmacoepidemiology and Drug Safety, 2019, 28, 625-631.	0.9	3
735	Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881983086.	1.4	15
736	Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 319.	1.0	43

#	ARTICLE	IF	Citations
737	Take Control: A randomized trial evaluating the efficacy and safety of self†versus physicianâ€managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1615-1624.	2.2	33
738	Design and development of the Hypoglycaemia Symptom Rating Questionnaire (HypoSRQ). Diabetes Research and Clinical Practice, 2019, 151, 187-197.	1.1	1
739	Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus. Diabetes, Obesity and Metabolism, 2019, 21, 1529-1542.	2.2	9
740	Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. BMJ: British Medical Journal, 2019, 365, l1226.	2.4	52
741	Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study). Diabetes Therapy, 2019, 10, 663-672.	1,2	11
742	Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2019, 21, 349-356.	2.2	21
743	Experiencia tras el cambio de insulina glargina U100 a glargina U300 en pacientes con diabetes tipo 1. Estudio tras un año de tratamiento en vida real. Endocrinologia, Diabetes Y NutriciÓn, 2019, 66, 210-216.	0.1	2
744	Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics, 2019, 58, 781-791.	1.6	103
745	Safety and efficacy of sodium glucose coâ€transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A metaâ€analysis of randomized controlled trials. Journal of Diabetes, 2019, 11, 645-655.	0.8	21
746	Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patientâ€level pooled analysis of EDITION 1, 2 and 3. Diabetes, Obesity and Metabolism, 2019, 21, 715-719.	2.2	6
747	A Modelâ€Based Metaâ€Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clinical Pharmacology and Therapeutics, 2019, 105, 1213-1223.	2.3	72
748	Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 355-364.	1.2	18
749	Is testing for postprandial hyperinsulinemic hypoglycemia after gastric bypass necessary?. Clinical Nutrition, 2019, 38, 444-449.	2.3	10
750	Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 226-233.	0.6	8
751	Associations Between the Knowledge of Different Food Categories and Glycemia in Chinese Adult Patients With Type 2 Diabetes. Clinical Nursing Research, 2020, 29, 313-321.	0.7	2
752	Cardivascular Risk Profile in Patients with Diabetes and Acromegaly or Cushing's Disease – Analysis from the DPV Database. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 104-110.	0.6	3
753	Prediction and prevention of hypoglycaemic events in type-1 diabetic patients using machine learning. Health Informatics Journal, 2020, 26, 703-718.	1.1	38
754	Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries. Acta Diabetologica, 2020, 57, 229-236.	1.2	4

#	Article	IF	CITATIONS
755	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. Diabetes Care, 2020, 43, 398-404.	4.3	23
756	Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2020, 180, 70.	2.6	26
757	Both hypo―and hyperglycaemia are associated with increased fracture risk in Japanese people with type 2 diabetes: theÂFukuoka Diabetes Registry. Diabetic Medicine, 2020, 37, 838-847.	1.2	11
758	Cognitive dysfunction during hypoglycemia in an elderly subject without diabetes. Diabetology International, 2020, 11, 150-154.	0.7	1
759	The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. Diabetes Technology and Therapeutics, 2020, 22, 411-421.	2.4	49
760	UK's nationally funded integrated islet transplant program. , 2020, , 613-623.		0
761	Risk of anyÂhypoglycaemia with newer antihyperglycaemic agents in patients withÂtype 2 diabetes: A systematic review and metaâ€analysis. Endocrinology, Diabetes and Metabolism, 2020, 3, e00100.	1.0	5
762	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICTâ€5): 52â€week results from a randomized, openâ€label, phase III clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 540-548.	2.2	22
763	Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technology and Therapeutics, 2020, 22, 85-95.	2.4	16
764	Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulinâ€naà ve people with type 2 diabetes: The EDITION AP randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 612-621.	2.2	17
765	Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetologica, 2020, 57, 549-558.	1.2	22
766	Treatment of type 1 diabetes complicated by problematic hypoglycemia. , 2020, , 391-406.		0
767	Associations between intra-arrest blood glucose level and outcomes of adult in-hospital cardiac arrest: A 10-year retrospective cohort study. Resuscitation, 2020, 146, 103-110.	1.3	8
768	Relative Hypoglycemia in Diabetic Patients With Critical Illness. Critical Care Medicine, 2020, 48, e233-e240.	0.4	31
769	Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy: data from the German/Austrian DPV registry. Diabetic Medicine, 2020, 37, 856-862.	1.2	10
770	Association of severe hypoglycemia with all-cause mortality and complication risks among patients with type 2 diabetes mellitus in China. Diabetes Research and Clinical Practice, 2020, 170, 108493.	1.1	6
771	Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study. Diabetes Therapy, 2020, 11 , 2909-2920.	1.2	0
772	Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882095829.	1.4	7

#	Article	IF	Citations
773	Diabetes patient's pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation. Therapeutic Advances in Drug Safety, 2020, 11, 204209862095393.	1.0	4
774	Incidence and Risk Factors Associated with Outpatient Hypoglycemia in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Study. Endocrine Research, 2020, 45, 217-225.	0.6	6
775	Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. Journal of Diabetes Research, 2020, 2020, 1-12.	1.0	5
776	Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis. Pharmacy (Basel, Switzerland), 2020, 8, 215.	0.6	2
777	Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach. Diabetes Therapy, 2020, 11, 2237-2255.	1.2	5
778	Effects of Coâ€administration of Sulfonylureas and Antimicrobial Drugs on Hypoglycemia in Patients with Type 2 Diabetes Using a Caseâ€Crossover Design. Pharmacotherapy, 2020, 40, 902-912.	1.2	3
779	Four weeks of highâ€intensity interval training (HIIT) improve the cardiometabolic risk profile of overweight patients with type 1 diabetes mellitus (T1DM). European Journal of Sport Science, 2021, 21, 1193-1203.	1.4	7
780	Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus. Scientific Reports, 2020, 10, 15384.	1.6	5
781	Safety and tolerability of onceâ€weekly GLPâ€1 receptor agonists in type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 43-60.	0.7	47
782	Metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001577.	1.2	3
783	Hypoglycemia prevention practice and its associated factors among diabetes patients at university teaching hospital in Ethiopia: Cross-sectional study. PLoS ONE, 2020, 15, e0238094.	1.1	7
784	The effect of eye movement desensitization and reprocessing on the fear of hypoglycemia in type 2 diabetic patients: a randomized clinical trial. BMC Psychology, 2020, 8, 82.	0.9	4
785	Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2427-2436.	2.2	5
786	(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. The Cochrane Library, 2020, 2020, CD005613.	1.5	25
787	Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?. Diabetes Care, 2020, 43, 821-827.	4.3	41
788	Emergency attendance for acute hyper- and hypoglycaemia in the adult diabetic population of the metropolitan area of Milan: quantifying the phenomenon and studying its predictors. BMC Endocrine Disorders, 2020, 20, 72.	0.9	5
789	Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. Diabetes Care, 2020, 43, 1512-1519.	4.3	11
790	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. Pharmacogenomics Journal, 2020, 20, 831-839.	0.9	5

#	Article	IF	CITATIONS
791	Experimental Models of Impaired Hypoglycaemia-Associated Counter-Regulation. Trends in Endocrinology and Metabolism, 2020, 31, 691-703.	3.1	11
792	Incidence of severe hypoglycemia and its association with serum adiponectin in Japanese patients with typeÂ1 and insulinâ€ŧreated typeÂ2 diabetes: The Fukuoka Diabetes Registry. Journal of Diabetes Investigation, 2020, 11, 1258-1264.	1.1	4
793	Hypoglycemia: Essential Clinical Guidelines. , 2020, , .		1
794	High anxiety and depressive symptoms in partners of type 1 diabetes persons in a sample of the Brazilian population. Diabetology and Metabolic Syndrome, 2020, $12,23$.	1.2	6
795	Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin. Diabetes, 2020, 69, 1815-1826.	0.3	12
796	Detection of Hypoglycemia Using Measures of EEG Complexity in Type 1 Diabetes Patients. Entropy, 2020, 22, 81.	1.1	13
797	Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technology and Therapeutics, 2020, 22, 516-526.	2.4	6
798	Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. Diabetes, Obesity and Metabolism, 2020, 22, 857-865.	2.2	6
799	Liraglutide as addâ€on to sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRAâ€ADD2SGLT2i, a 26â€week, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 929-937.	2.2	29
800	Associations Between the Time in Hypoglycemia and Hypoglycemia Awareness Status in Type 1 Diabetes Patients Using Continuous Glucose Monitoring Systems. Diabetes Technology and Therapeutics, 2020, 22, 787-793.	2.4	16
801	Hypoglycemia, Malnutrition and Body Composition. Advances in Experimental Medicine and Biology, 2020, 1307, 71-84.	0.8	8
802	Predicting and Preventing Nocturnal Hypoglycemia in Type 1 Diabetes Using Big Data Analytics and Decision Theoretic Analysis. Diabetes Technology and Therapeutics, 2020, 22, 801-811.	2.4	19
803	Pediatric-Onset Postural Orthostatic Tachycardia Syndrome in a Single Tertiary Care Center. Journal of Child Neurology, 2020, 35, 526-535.	0.7	13
804	Application of medium-term metrics for assessing glucose homoeostasis: Usefulness, strengths and weaknesses. Diabetes and Metabolism, 2021, 47, 101173.	1.4	7
805	Sodium–glucose cotransporterÂ2 inhibitors reduce dayâ€toâ€day glucose variability in patients with typeÂ1 diabetes. Journal of Diabetes Investigation, 2021, 12, 176-183.	1.1	8
806	<scp>Longâ€term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp> â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	2.2	21
807	Extensive scalp defect with exposed bone after a head trauma. Internal and Emergency Medicine, 2021, 16, 501-502.	1.0	0
808	Human plasmaâ€derived alpha ₁ â€proteinase inhibitor in patients with newâ€onset type 1 diabetes mellitus: A randomized, placeboâ€controlled proofâ€ofâ€concept study. Pediatric Diabetes, 2021, 22, 192-201.	1.2	6

#	Article	IF	CITATIONS
809	Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study. Diabetes Therapy, 2021, 12, 247-259.	1.2	0
810	Effects of telemedicine intervention on the management of diabetic complications in type 2 diabetes. International Journal of Diabetes in Developing Countries, 2021, 41, 322-328.	0.3	5
811	Factors influencing hospital conveyance following ambulance attendance for people with diabetes: A retrospective observational study. Diabetic Medicine, 2021, 38, e14384.	1.2	1
812	Autoreactive T cell profiles are altered following allogeneic islet transplantation with alemtuzumab induction and re-emerging phenotype is associated with graft function. American Journal of Transplantation, 2021, 21, 1027-1038.	2.6	5
813	Cognitive Impairment Among Older Adults With Diabetes Mellitus in Puducherry: A Community-Based Cross-Sectional Study. Cureus, 2021, 13, e12488.	0.2	5
814	Acute Diabetes Complications. Contemporary Endocrinology, 2021, , 105-124.	0.3	0
815	Sensitivity-Enhanced Fluidic Glucose Sensor Based on a Microwave Resonator Coupled With an Interferometric System for Noninvasive and Continuous Detection. IEEE Transactions on Biomedical Circuits and Systems, 2021, 15, 1017-1026.	2.7	11
816	Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of type 1 diabetes mellitus. Archives of Endocrinology and Metabolism, 2021, 65, 164-171.	0.3	1
817	Recurrent Hypoglycemia in Diabetic Patient With Hypopituitarism: The Houssay Phenomenon. Cureus, 2021, 13, e13422.	0.2	2
818	Diabetic kidney disease and transplantation options. Practical Diabetes, 2021, 38, 28.	0.1	0
819	Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. Clinical Pharmacology in Drug Development, 2021, 10, 453-462.	0.8	15
820	DIY artificial pancreas: A narrative of the first patient and the physicians' experiences from India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 615-620.	1.8	8
821	Transdermal delivery of a somatostatin receptor type 2 antagonist using microneedle patch technology for hypoglycemia prevention. Drug Delivery and Translational Research, 2022, 12, 792-804.	3.0	13
822	Conflicting Logics in a Changing Action Space: Challenges Related to Type 1 Diabetes in Work Life. Qualitative Health Research, 2021, 31, 104973232110018.	1.0	1
823	Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002099.	1.2	4
824	Effect of a single bout of morning or afternoon exercise on glucose fluctuation in young healthy men. Physiological Reports, 2021, 9, e14784.	0.7	7
825	The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review. Diabetes Research and Clinical Practice, 2021, 174, 108752.	1.1	20
826	Personalized Type 2 Diabetes Management Using a Mobile Application Integrated with Electronic Medical Records: An Ongoing Randomized Controlled Trial. International Journal of Environmental Research and Public Health, 2021, 18, 5300.	1.2	4

#	Article	IF	Citations
827	A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, singleâ \in enter study and the generation of www.emergencyprotocol.net. Journal of Inherited Metabolic Disease, 2021, 44, 1124-1135.	1.7	10
828	Practical aspects of usage of insulin in India: Descriptive review and key recommendations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 937-948.	1.8	1
829	Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis. Clinical Therapeutics, 2021, 43, 836-843.e4.	1.1	9
830	DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2021, 9, e002215.	1.2	2
831	Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. Diabetes Therapy, 2021, 12, 1915-1927.	1.2	15
832	Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies. Diabetes Research and Clinical Practice, 2021, 176, 108848.	1.1	4
833	Notification of biochemistry critical results and its clinical impact on outpatient care: experience in a Spanish tertiary hospital. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1777-1783.	1.4	2
834	The paradox of the glycemic gap: Does relative hypoglycemia exist in critically ill patients?. Clinical Nutrition, 2021, 40, 4654-4661.	2.3	10
835	Quality of Glycemic Control: Assessment Using Relationships Between Metrics for Safety and Efficacy. Diabetes Technology and Therapeutics, 2021, 23, 692-704.	2.4	14
836	Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?. Biomolecules, 2021, 11, 1281.	1.8	5
837	Association of early glycemic change with short-term mortality in lobar and non-lobar intracerebral hemorrhage. Scientific Reports, 2021, 11, 16059.	1.6	1
838	Longâ€term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104â€week extension to a 52â€week randomized, phase 3 study and liver fat <scp>MRI</scp> substudy. Diabetes, Obesity and Metabolism, 2022, 24, 61-71.	2.2	4
839	Not All Type-2-Diabetes Patients Increase Body Mass Index After Initiating Insulin: Results of Latent Class Analysis from the DPV Registry. Diabetes Technology and Therapeutics, 2021, 23, 799-806.	2.4	1
840	Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update. Expert Opinion on Pharmacotherapy, 2021, 22, 1-9.	0.9	3
841	Chasing the Offending Medication. Journal of Clinical Psychopharmacology, 2021, Publish Ahead of Print, 698-699.	0.7	2
842	Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 961-974.	0.6	2
843	Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2021, 35, 107995.	1.2	0
844	Hyperinsulinemic Hypoglycemia in Three Generations of a Family with Glucokinase Activating Mutation, c.295T>C (p.Trp99Arg). Genes, 2021, 12, 1566.	1.0	3

#	Article	IF	CITATIONS
845	Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study. Clinical Diabetes and Endocrinology, 2021, 7, 2.	1.3	3
846	Definitions and reporting of hypoglycaemia in trials of long-acting insulin analogues in people with type 1 diabetes mellitus. The Cochrane Library, $0,,$	1.5	1
851	The Utility of Continuous Subcutaneous Insulin Infusion for Management of Mild to Moderate Diabetic Ketoacidosis. American Journal of Internal Medicine, 2016, 4, 43.	0.1	1
852	Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort. PLoS ONE, 2016, 11, e0148630.	1.1	18
853	The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS ONE, 2018, 13, e0190579.	1.1	2
854	Post-Prandial Plasma Glucose Less Than or Equal to 70 mg/dL Is Not Uncommon in Young Japanese Women. Journal of Clinical Medicine Research, 2017, 9, 680-686.	0.6	4
855	Effects of Stevia Rebaudiana on Glucose Homeostasis, Blood Pressure and Inflammation: A Critical Review of Past and Current Research Evidence. International Journal of Clinical Research & Trials, 2020, 5, .	1.6	14
856	Quality of Life of Insulin-Naà ve People with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs after the Addition of Insulin Glargine, in Every Day Clinical Practice in Greece. Journal of Diabetes, Metabolic Disorders & Control, 2015, 2, .	0.2	1
857	An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England. European Endocrinology, 2017, 13, 81.	0.8	9
858	Is biochemical hypoglycemia necessary during an insulin tolerance test?. Archives of Endocrinology and Metabolism, 2020, 64, 82-88.	0.3	4
859	Detecting Hypoglycemia Incidents Reported in Patients' Secure Messages: Using Cost-Sensitive Learning and Oversampling to Reduce Data Imbalance. Journal of Medical Internet Research, 2019, 21, e11990.	2.1	26
860	Automatic Detection of Hypoglycemic Events From the Electronic Health Record Notes of Diabetes Patients: Empirical Study. JMIR Medical Informatics, 2019, 7, e14340.	1.3	17
861	Road to Hierarchical Diabetes Management at Primary Care (ROADMAP) Study in China: Protocol for the Statistical Analysis of a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e18333.	0.5	1
862	The Diabits App for Smartphone-Assisted Predictive Monitoring of Glycemia in Patients With Diabetes: Retrospective Observational Study. JMIR Diabetes, 2020, 5, e18660.	0.9	11
863	The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care, 2006, 29, 20-5.	4.3	65
864	The altered circadian pattern of basal insulin requirements – an early marker of autoimmune polyendocrine syndromes in type 1 diabetes mellitus. Endocrine Regulations, 2020, 54, 126-132.	0.5	2
865	Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. Health Technology Assessment, 2018, 22, 1-112.	1.3	26
866	Blood electrolyte disturbances during severe hypoglycemia in Korean patients with type 2 diabetes. Korean Journal of Internal Medicine, 2015, 30, 648-656.	0.7	6

#	Article	IF	CITATIONS
867	Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & Dolus aspart in patients with poorly controlled type 2 diabetes mellitus - A pilot study. Indian Journal of Medical Research, 2012, 135, 78.	0.4	8
868	Traumatic injuries in patients with diabetes mellitus. Journal of Emergencies, Trauma and Shock, 2016, 9, 64.	0.3	16
869	A retrospective study on epidemiology of hypoglycemia in Emergency Department. Indian Journal of Endocrinology and Metabolism, 2017, 21, 119.	0.2	15
870	Reported hypoglycemia in Type 2 diabetes mellitus patients: Prevalence and practices-a hospital-based study. Indian Journal of Endocrinology and Metabolism, 2017, 21, 148.	0.2	21
871	Syncope and Hypoglycemia. International Journal of Clinical Medicine, 2011, 02, 129-132.	0.1	4
872	Causes of Fasting-Evoked en Route Hypoglycemia in Diabetes (FEEHD): A Case Series Study. International Journal of Clinical Medicine, 2012, 03, 751-757.	0.1	4
873	Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice. International Journal of Clinical Medicine, 2016, 07, 653-667.	0.1	5
874	Predictors of hypoglycemia in insulin-treated patients with type 2 diabetes mellitus in Basrah. World Journal of Diabetes, 2016, 7, 470.	1.3	5
875	Predictores de Calidad de Vida en Pacientes con Diabetes Mellitus Tipo 1. Clinica Y Salud, 2010, 21, 35-47.	0.3	13
876	Impact of Insulin Delivery Method on Hypoglycemia Incidence in Pediatric Type 1 Diabetes Mellitus Patients. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2017, 71, 391.	0.4	3
877	Severe hypoglycaemia requiring the assistance of emergency medical services - frequency, causes and symptoms. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 271-277.	0.2	8
878	CSII is related to more stable glycemia in adults with type 1 diabetes. Endocrine, 2021, , 1.	1.1	1
879	Hypoglycemia Among Type 1 Diabetes Patients After Insulin Use in Southwest Ethiopia. Frontiers in Endocrinology, 2021, 12, 684570.	1.5	5
880	Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open, 2021, 11, e049595.	0.8	2
881	Diabetes Mellitus and Cardiac Rehabilitation in Clinical Practice., 2007,, 197-209.		0
882	Hypoglycemia in Type 2 Diabetes. , 2007, , 227-235.		0
884	Fear of Hypoglycaemia: Defining a Minimum Clinically Important Difference. SSRN Electronic Journal, 0, , .	0.4	0
885	Hypoglycemia in Diabetes Mellitus. , 2010, , 297-312.		0

#	ARTICLE	IF	CITATIONS
886	Hypoglycaemia in Type 2 Diabetes $\hat{a} \in \text{Clinical Consequences}$ and Impact on Treatment. European Endocrinology, 2010, 06, 29.	0.8	2
887	Hypoglycemia and Hypoglycemic Syndromes. , 2010, , 873-896.		0
889	Management of Diabetes Mellitus in Children. , 2010, , 916-942.		0
891	The Experience of Hypoglycaemia and Strategies Used For Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review. JBI Database of Systematic Reviews and Implementation Reports, 2011, 9, 2063-2104.	1.7	O
892	References, Bibliography & Dirther Reading., 2012, , 287-306.		0
894	4. Prevention and Management of Hypoglycemia in the Active Patient with Diabetes. Translational Endocrinology & Metabolism, 2012, , 115-136.	0.2	0
895	The Efficacy and Safety of Saxagliptin in Haemodialysis Patients. Open Journal of Nephrology, 2013, 03, 83-88.	0.0	0
896	A study of emergency visits for hypoglycemia cases. Nihon Kyukyu Igakukai Zasshi, 2013, 24, 391-398.	0.0	0
897	Hypoglycaemia in Diabetes. , 2014, , 429-443.		0
901	Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Korean Journal of Medicine, 2014, 87, 501.	0.1	1
902	Medical Practice Variations in Diabetes Mellitus. , 2014, , 1-40.		1
903	Recurrent hypoglycaemia in type 1 diabetes mellitus resulting from intensive academic activity: an illustrative case report. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2014, 21, 43-46.	0.3	O
905	Feasibility and safety of continuous glucose monitoring systems in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions. Clinical and Investigative Medicine, 2015, 38, 384.	0.3	0
906	Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation. Part 2. Clinical Efficacy and Safety. Mìžnarodnij EndokrinologìÄnij Žurnal, 2016, .	0.1	O
907	Localization of Pancreatic Insulinomas with Arterial Stimulation by Calcium and Hepatic Venous Sampling - Presentation of a Single Centre Experience. Acta Endocrinologica, 2016, 12, 55-62.	0.1	0
908	Stenotic atherosclerotic lesions of carotid arteries in type 2 diabetes: the most significant risk factors. Family Medicine, 2016, .	0.1	0
909	New Basal Insulin Toujeo Solostar: Increased Therapeutic Potential for the Control of Dysglycaemia in Diabetes Mellitus. Mìžnarodnij EndokrinologìÄnij Žurnal, 2016, .	0.1	0
911	Islet Cell or Pancreas Transplantation. Endocrinology, 2018, , 655-693.	0.1	0

#	Article	IF	CITATIONS
912	Self-Reported Hypoglycemia in Insulin-Treated Patients with Diabetes: Results from the Philippines Cohort of the International Operations Hypoglycemia Assessment Tool (IO HAT) Study. Journal of the ASEAN Federation of Endocrine Societies, 2018, 33, 12-21.	0.1	0
913	Hypoglycaemia among Insulin-Treated Patients with Diabetes: Southeast Asia Cohort of IO HAT Study. Journal of the ASEAN Federation of Endocrine Societies, 2018, 33, 28-36.	0.1	3
914	Désordres glycémiques., 2019, , 53-90.		0
916	Frequency and predisposing factors for drug-induced hypoglycemia in patients with type-2 diabetes mellitus. Journal of Research in Pharmacy Practice, 2019, 8, 64.	0.2	3
917	Hypoglycaemia Among Insulin-Treated Patients with Diabetes: Evaluation of the United Arab Emirates cohort of the International Operations-Hypoglycaemia Assessment Tool study. Sultan Qaboos University Medical Journal, 2019, 18, 447.	0.3	2
918	Factors associated with In-Hospital Mortality among Patients with Diabetes Admitted for Lower Extremity Infections. Journal of the ASEAN Federation of Endocrine Societies, 2019, 34, 36-43.	0.1	3
919	A Prospective, Randomized, Open Label, Single-Centre Study for Assessment of Safety and Effectiveness of Recombinant Human Insulin 30/70 + Insulin Glulisine compared to Recombinant Human Insulin NPH + Regular in the Management of Type 2 Diabetes Mellitus Patients in the Philippines Journal of Medicine University of Santo Tomas, 2019, 3, 260-269.	0.0	0
920	Early and Late Dumping Syndromes. , 2020, , 257-261.		0
923	Effects of high and low sucrose-containing beverages on blood glucose and hypoglycemic-like symptoms. Physiology and Behavior, 2020, 222, 112916.	1.0	5
924	Demographic Influences and Health Disparities. , 2020, , 169-197.		O
926	Acil servise başvuran hipoglisemili olguların etiyolojik yönden incelenmesi. Anadolu Güncel Tıp Dergisi, 2020, 2, 42-46.	0.0	0
927	Self-reported hypoglycaemia in insulin-treated patients with diabetes mellitus: results from the Singapore cohort of the International Operations Hypoglycaemia Assessment Tool study. Singapore Medical Journal, 2020, 61, 129-136.	0.3	5
930	Observational study of the relative efficacy of insulin-glucose treatment for hyperkalaemia in patients with liver cirrhosis. BMJ Open, 2021, 11, e051201.	0.8	0
931	Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review. Current Osteoporosis Reports, 2021, 19, 637-643.	1.5	0
932	Hypoglycemia in Type 2 Diabetes. , 2008, , 193-201.		0
934	Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vascular Health and Risk Management, 2009, 5, 121-8.	1.0	8
935	Glucose counterregulatory responses to hypoglycemia. Pediatric Endocrinology Reviews, 2011, 9, 463-73; quiz 474-5.	1.2	87
936	Managing post stroke hyperglycaemia: moderate glycaemic control is better? An update. EXCLI Journal, 2014, 13, 825-33.	0.5	6

#	Article	IF	CITATIONS
937	The Use of Antidiabetic, Antihypertensive, and Lipid-lowering Medications in the Elderly Dying with Advanced Cancer. Indian Journal of Palliative Care, 2019, 25, 124-126.	1.0	0
938	Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT). BMJ Open, 2020, 10, e040117.	0.8	O
939	A Single Center Study on the Risks of Peri-Intervention Stroke in Thoracic Endovascular Aortic Repair (TEVAR) and Endovascular Abdominal Aortic Repair (EVAR). Journal of Cardiovascular Development and Disease, 2022, 9, 10.	0.8	0
940	Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar <scp>Insulinâ€R</scp> with the <scp>US</scp> â€icensed <scp>Humulin® R</scp> formulation in healthy subjects: Results from the <scp>RHINE</scp> â€i (<scp>Recombinant Human INsulin Equivalenceâ€i</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 713-721.	2.2	7
941	Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT). BMJ Open, 2020, 10, e040117.	0.8	4
942	Hypoglycemia requiring paramedic assistance among adults in southwestern Ontario, Canada: a population-based retrospective cohort study. CMAJ Open, 2021, 9, E1260-E1268.	1.1	1
943	The Impact of Hypoglycemia on Patients with Diabetes Mellitus: A Cross-Sectional Analysis. Journal of Clinical Medicine, 2022, 11, 626.	1.0	5
944	Impact of fear of hypoglycaemia on self-management in patients with type 2 diabetes mellitus: structural equation modelling. Acta Diabetologica, 2022, 59, 641-650.	1.2	7
945	Anticipated Basal Insulin Reduction to Prevent Exercise-Induced Hypoglycemia in Adults and Adolescents Living with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 307-315.	2.4	4
946	Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 578-591.	1.8	3
947	Hypoglycemic Events in the Emergency Department (HEED). Endocrine Practice, 2022, , .	1.1	О
948	Considerations and challenges of islet transplantation and future therapies on the horizon. American Journal of Physiology - Endocrinology and Metabolism, 2022, 322, E109-E117.	1.8	18
949	Evaluating the Incidence and Risk Factors Associated With Mild and Severe Hypoglycemia in Insulin-Treated Type 2 Diabetes. Value in Health Regional Issues, 2022, 30, 9-17.	0.5	5
951	Treatment Patterns and Outcomes Before and After HumulinÂR U-500 Initiation Among US Patients with TypeÂ2 Diabetes Previously Prescribed â‰ã€‰200ÂUnits/day of U-100 Insulin. Diabetes Therapy, 2022, 13,	465-479.	4
952	Emergency Glucagon: a Focused Review of Psychosocial Experiences of Rescue Drugs for Type 1 Diabetes. Current Diabetes Reports, 2022, 22, 189.	1.7	5
953	Identification and management of GCK-MODY complicating pregnancy in Chinese patients with gestational diabetes. Molecular and Cellular Biochemistry, 2022, 477, 1629-1643.	1.4	4
955	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 2022, 45, 1476-1481.	4.3	6
956	Ramadan Fasting Among Older Children and Adolescents With Type 1 Diabetes Mellitus: A Real-World Study From the UAE. Frontiers in Nutrition, 2022, 9, 786678.	1.6	3

#	Article	IF	CITATIONS
957	Randomised controlled trial of an innovative hypoglycaemia pathway for self-care at home and admission avoidance: a partnership approach with a regional ambulance trust. British Paramedic Journal, 2022, 6, 3-10.	0.3	0
958	Hypoglycemia-Exacerbated Mitochondrial Connexin 43 Accumulation Aggravates Cardiac Dysfunction in Diabetic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2022, 9, 800185.	1.1	7
959	Hypoglycemia in Pregnancies Following Gastric Bypassâ€"a Systematic Review and Meta-analysis. Obesity Surgery, 2022, 32, 2047-2055.	1.1	5
960	Biosimilar Insulin Aspart Premix SAR341402 MixÂ70/30 Versus Originator Insulin Aspart MixÂ70/30 (NovoMixÂ30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLIÂM). Diabetes Therapy, 2022, 13, 1053.	1.2	2
961	Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and metaâ€analysis of randomised clinical trials. Journal of Human Nutrition and Dietetics, 2022, 35, 1030-1042.	1.3	14
962	Perception and attitude about systemic health and periodontal disease among dentistry undergraduates. Oral Health & Preventive Dentistry, 2013, 11, 383-8.	0.3	1
964	Media Portrayal of Type 1 Diabetes in North American Television and Film. Canadian Journal of Diabetes, 2022, 46, 740-742.	0.4	2
965	Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with <scp>US</scp> â€icensed HUMULIN® 70/30 formulation in healthy subjects: Results from the <scp>RHINE</scp> â€3 (R ecombinant H uman) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 457	⊉ d₂(<scp:< td=""><td> >4b>IN</td></scp:<>	 > 4 b>IN
966	Association between Intra-Arrest Blood Glucose Level and Outcomes of Resuscitation at the Emergency Department: A Retrospective Study. Journal of Clinical Medicine, 2022, 11, 3067.	1.0	1
967	Dynamics of Hemoglobin A1c, Body Mass Index, and Rates of Severe Hypoglycemia in 4434 Adults with Type 1 or Type 2 Diabetes After Initiation of Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2022, 24, 763-769.	2.4	5
968	Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin. Diabetes Therapy, 0, , .	1.2	1
969	Understanding Hypoglycemia in the Real World. Science of Diabetes Self-Management and Care, 0, , 263501062211028.	0.9	O
971	Efficacy and safety of low dose insulin infusion against standard dose insulin infusion in children with diabetic ketoacidosis- An open labelled randomized controlled trial. Indian Journal of Endocrinology and Metabolism, 2022, 26, 173.	0.2	2
972	Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest. Diabetes Care, 0, , .	4.3	3
973	Combined laparoscopic Roux-en-Y gastric bypass reversal and gastric banding to treat severe hyperinsulinemic hypoglycemia: A case report and surgical video. International Journal of Surgery Case Reports, 2022, 96, 107271.	0.2	1
974	Blood Glucose Fluctuation in Older Adults with Diabetes Mellitus and End-Stage Renal Disease on Maintenance Hemodialysis: An Observational Study. Diabetes Therapy, 2022, 13, 1353-1365.	1.2	1
975	Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial. Current Medical Research and Opinion, 0, , 1-34.	0.9	О
976	Prediction Models for Prognosis of Hypoglycemia in Patients with Diabetes: A Systematic Review and Meta-Analysis. Biological Research for Nursing, 2023, 25, 41-50.	1.0	2

#	Article	IF	CITATIONS
977	Comprehensive evaluation of patterns of hypoglycemia unawareness (HUA) and glycemic variability (GV) in patients with fibrocalculous pancreatic diabetes (FCPD): A cross-sectional study from South India. PLoS ONE, 2022, 17, e0270788.	1.1	1
978	Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review. Diabetologia, 2022, 65, 1601-1612.	2.9	6
980	Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study. Current Medical Research and Opinion, 0, , 1-8.	0.9	1
981	A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes. Acta Diabetologica, 2022, 59, 1453-1460.	1.2	3
982	Management of Perioperative Medical Emergencies. , 2022, , 143-163.		0
983	Total Pancreatectomy With Islet Autotransplantation as an Alternative to High-risk Pancreatojejunostomy After Pancreaticoduodenectomy. Annals of Surgery, 2023, 277, 894-903.	2.1	8
984	Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (NovologÂ $^{\odot}$) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study. BioDrugs, 2022, 36, 761-772.	2.2	2
985	Pathophysiology and management of hypoglycemia in diabetes. Annals of the New York Academy of Sciences, 2022, 1518, 25-46.	1.8	3
986	Risk factors and outcomes of severe hypoglycaemia requiring hospital admission: a retrospective study. Practical Diabetes, 2022, 39, 19.	0.1	1
987	Hypoglycemia in type 1 diabetes: a burden to worry about during treatment. Archives of Endocrinology and Metabolism, 2022, 66, 776-779.	0.3	0
988	Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 3601-3615.	1.1	1
989	<scp>ISPAD /scp> Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 2022, 23, 1322-1340.</scp>	1.2	19
990	Comparison of gliclazide <i>vs </i> linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World Journal of Diabetes, 0, 13, 1168-1183.	1.3	0
991	Dextrose Administration and Resuscitation Outcomes in Patients with Blood Sugar Less Than 150 mg/dL during Cardiopulmonary Resuscitation: An Observational Data Analysis. Journal of Clinical Medicine, 2023, 12, 460.	1.0	1
992	Hypoglycemic syndrome in emergency medicine (lecture). Emergency Medicine, 2022, 18, 8-17.	0.0	0
993	Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 259-273.	1.1	5
994	Glucose Counterregulation. Veterinary Clinics of North America - Small Animal Practice, 2023, 53, 551-564.	0.5	0
995	Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia. Journal of Investigative Medicine, 2023, 71, 400-410.	0.7	1

#	Article	IF	CITATIONS
996	Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis. Canadian Journal of Diabetes, 2023, 47, 368-377.	0.4	4
997	Steroid supplementation before minor oral surgical procedures in patients taking long-term glucocorticoids. Journal of the American Dental Association, 2023, 154, 373-383.e3.	0.7	О
998	The use of isCGM leads to marked reduction in severe hypoglycemia requiring emergency medical service or hospital admission and diabetic ketoacidosis in adult type 1 diabetes patients. Acta Diabetologica, 0 , , .	1,2	0
999	Development of an artificial intelligence system to identify hypoglycaemia via ECG in adults with type 1 diabetes: protocol for data collection under controlled and free-living conditions. BMJ Open, 2023, 13, e067899.	0.8	4
1012	Islet Allotransplantation., 2023,, 1157-1204.		0
1016	Continuous glucose monitoring in people with diabetes and end-stage kidney disease—review of association studies and Evidence-Based discussion. Journal of Nephrology, 0, , .	0.9	O
1022	Hypoglycemia, insulin resistance, and cardiovascular disease: A possible link., 2024, , 597-608.		0